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T cells are a key component of the adaptive immune system, which act as both 
coordinators and effectors of immunity.  As such, T cells are instrumental in protecting the 
host from invading pathogens and malignancies.  The different stages of T cell activation, 
expansion and contraction are integrated with systemic inflammation and the control of 
microbial or cancer cell growth.  However, when activated inappropriately due to 
cell-intrinsic or cell-extrinsic factors, T cells contribute to a wide spectrum of diseases such as 
T-cell acute lymphoblastic leukemia (T-ALL), autoimmune disorders, or organ transplant 
rejection [1].   
Glucocorticoid receptor (GR), combined with glucocorticoid (GC), represses cytokine 
and interleukin gene transcription and triggers programmed cell death (apoptosis) in T cells.  
The GC-induced apoptosis may help to eliminate developing T cells or thymocytes that are 
differentiating improperly [2].  Therefore, GCs are used as first choice drugs in the treatment 
of patients with ALL or several autoimmune diseases as still essential components of 
treatment [3].  However, lots of patients show poor response to monotherapy with 
prednisone [4].   
Despite of improved supportive care, the prognosis of patients with GC resistant T‑ALL 
who fail to obtain a complete hematological remission or those whose disease relapses after a 
transient initial response remains poor [4, 5].  According to the Japanese Clinical Guidelines 
for Childhood Leukemia and Lymphoma (2016), ALL202-U treatment schedule is 
recommended to ALL patients [6].  In this schedule, high-dose anti-leukemic drugs such as 
methotrexate, vincristine, THP-adriamycin, cyclophosphamide, L-asparaginase, cytarabine 
and mercaptopurine are inevitably recommended to these patients.  Unfortunately, however, 
these aggressive treatment regimens are often associated with severe acute toxicities and 
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long-term side effects, especially for pediatric T-ALL [7].  Faced with these clinical 
challenges, it is urgent to develop more effective and less toxic therapy strategy for T-ALL. 
GC therapy combined with immunosuppressive drugs is effective to suppress acute 
allograft rejection in organ transplantations.  However, approximately 30% of the patients 
receiving kidney transplantation show no or an inadequate response to the GC therapy, which 
is an important risk factor for inferior renal allograft outcome [8].  Other immunosuppressive 
drugs such as basiliximab, calcineurin inhibitors, mTOR inhibitors and purine-synthesis 
inhibitors are alternative strategy for prevention of acute allograft rejection [9, 10].  
Regardless of therapeutic drug monitoring based therapy, large individual variation in clinical 
efficacy of calcineurin inhibitors has been observed.  Such individual variation in clinical 
efficacy of immunosuppressive drugs might also be observed in many cases of organ 
transplant recipients in not only pharmacokinetic but also pharmacodynamic basis [11].  
Taking together with the above clinical problems, it is worthy to develop new therapeutic 
approaches, which can decrease the doses, and therefore adverse effects, of GCs and other 
immunosuppressive drugs for organ transplant recipients. 
GCs exert their functions by binding to the GR, a transcription factor encoded by the 
NR3C1 gene.  In the absence of GC, GR is predominantly localized in the cytoplasm in a 
complex containing heat shock proteins, immunophilins, and other factors that prevent its 
degradation and enhance its affinity for its ligand.  Upon ligand binding, GR undergoes a 
conformational change, resulting in partial dissociation from the chaperone complex and 
nuclear translocation.  In the nucleus, the GC-GR complex acts as a transcriptional regulator 
of many target-genes by binding on GC response element (GRE) located to their promoter 
[12].  Several molecular mechanisms concerning the GC resistance have now been identified.  
P-glycoprotein, an ATP-binding cassette transporter, is encoded by the multidrug-resistance 
gene MDR 1.  It transports many lipophilic drugs including GC out of cells.  Therefore, 
P-glycoprotein-mediated drug efflux is the first barrier located at the target cell surface.  Our 
previous studies have disclosed the relationship between P-glycoprotein function of peripheral 
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T lymphocyte subsets and GC response in myasthenia gravis patients [13].  Activation of 
mitogen-activated protein kinase (MAPK) pathways by certain cytokines in the cytoplasm 
also impeded the GR translocation, thus decreasing the pharmacodynamics of GCs [14].  In 
addition to these points, abnormal GR expression also contributes to GC resistance.  A 
decreased number of GR  or increased expression of GR β was observed in GC resistant 
patients of several diseases, including asthma, rheumatoid arthritis and inflammatory bowel 
disease [14, 15].  Moreover, genetic factors also determine GC responsiveness because GC 
resistant asthma is often related with families [14].  In my study, I focused on P-glycoprotein 
and MAPK mediated GC resistance, since these molecular mechanisms have been suggested 
to be implicated with GC resistance in several autoimmune diseases and lymphocytic 
leukemia [2, 14, 15].  Blocking these negative factors is a possible strategy to overcome the 
GC resistance.   
Tetrandrine (TET), derived from a medicinal plant Stephania tetrandra S. Moore (中国
産防已), is a bisbenzylisoquinoline alkaloid, and was approved for treating patients with 
silicosis and rheumatoid arthritis in China since 1981.  Our previous study revealed that TET 
enhanced the cytotoxicity of anticancer drugs by reversing P-glycoprotein-mediated 
daunorubicin resistance in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 
cells [16].  Meanwhile, TET alone at concentrations of μM showed suppressive effect on 
proliferation of T cells stimulated with phorbol 12-myristate 13-acetate and anti CD28 
antibody [17, 18].  Recent investigations also firmly supported that TET would be a potential 
candidate for cancer chemotherapy [19, 20].  TET upregulated the caspase cascade protein 
(cleaved PARP, cleaved caspase-3 and cleaved caspase-9) and inhibited the phosphorylation 
of Akt/mTOR, resulted in apoptosis induction on human gastric cancer cells [21].  From 
these points of view, I was encouraged to investigate inhibitory effects of TET on human T 
cells and its synergic efficacy on GC pharmacodynamics.   
Interestingly, botanical sources of Boui are totally different between China and Japan.  
Chinese Pharmacopeia (2015 edition) lists the Radix Stephaniae Tetrandrae as Boui, while 
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Caulis Sinomenii is collected as the herb of Boui in Japanese Pharmacopeia (17
th
 edition).  
Sinomenine (SN) is the main active alkaloid of herbal plant Sinomenium acutum (Thunb.) (日
本産防已).  Lots of studies also indicated that SN showed anti-rheumatoid arthritis efficacy 
by inhibiting the proliferation of lymphocytes [22, 23].  Moreover, SN was reported to 
down-regulate P-glycoprotein expression and inhibit the efflux function of P-glycoprotein in 
multidrug resistant bladder cancer cell model 253J/DOX [24].  Hence, in the present study, I 
also evaluated the potential additive effect of SN on GC pharmacodynamics in vitro to 
suppress the proliferation of human T lymphocytes.   
Until now, GC resistance or insensitivity still represents an important barrier for the 
effective treatment of T cell-mediated diseases, such as T-ALL, autoimmune diseases, and 
organ transplant rejection.  To find the potential new therapeutic strategy, my present study 
was designed to examine the inhibition effect of TET and SN, which were isolated from 
Stephania tetrandra S. Moore (中国産防已) and Sinomenium acutum (Thunb.) (日本産防已) 




Tetrandrine and cepharanthine induce apoptosis through caspase cascade 
regulation, cell cycle arrest, MAPK activation and PI3K/Akt/mTOR signal 
modification in steroid resistant human leukemia Jurkat T cells 
1.1 INTRODUCTION 
Acute lymphoblastic leukemia (ALL) is a heterogeneous hematologic disease 
characterized by the proliferation of immature lymphoid cells in the bone marrow, peripheral 
blood, and other organs [25].  Approximately 75 to 80% of ALL develop in children [26].  
Optimal use of antileukemic drugs and improved supportive care in contemporary clinical 
trials has improved the 5-year survival rate of childhood ALL above 85% in developed 
countries [27].  However, the majority (~ 80%) of relapses occurs within 2 years of 
diagnosis in T cell ALL (T-ALL), and the prognosis after relapse is dismal, with a 5-year 
survival of less than 10% [28].   
Tetrandrine (TET, Fig 1-1A) at concentrations of μM was reported to suppress 
proliferation of T cells stimulated with phorbol 12-myristate 13-acetate and anti CD28 
antibody [17, 18].  Meanwhile, recent investigations firmly supported that TET would be a 
potential candidate as a cancer chemotherapeutic agent [19, 20].  Moreover, one of the 
clinical trials for TET showed that TET, in combination with traditional chemotherapeutic 
drugs, had potential-reversing effect for the treatment of refractory and relapsed acute 
myelogenous leukemia [29].  The above information hints that TET could inhibit the 
proliferation of both T cells and cancer cells.  Sharing the similar chemical skeleton with 
TET, cepharanthine (CEP, Fig. 1-1A) is another bisbenzylisoquinoline alkaloid isolated from 
the plant Stephania cepharantha Hayata [30].  From these points of view, I was encouraged 
to investigate the cytotoxic effects of TET and CEP on human T-lymphoblastic leukemia cells 
having features of both T cells and cancer cells.   
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Since poor response to GC is one of the strongest predictors of adverse outcome for the 
treatment of childhood T-ALL [4], GC-resistant human leukemia Jurkat T cell line [31], a 
well-established T-ALL tumor line from the peripheral blood of a 14-year-old boy [32], was 
used in the present study to examine potential efficacy of TET and CEP and their underlying 
action mechanisms focusing on caspase cascade, cell cycle, MAPK and PI3K/Akt/mTOR 
signaling pathway.   
1.2 MATERIALS AND METHODS 
1.2.1 Drugs and reagents 
RPMI 1640 and fetal bovine serum (FBS) were purchased from Gibco BRL (Grand 
Island, NY, USA).  TET (purity: more than 98%) and CEP (purity: more than 98%) were 
obtained from Sigma Aldrich and Cayman Chemical Company, respectively.  Camptothecin 
(CPT) was provided by Wako Pure Chemical Industries, Ltd., Japan.  Drugs were dissolved 
in dimethyl sulfoxide (DMSO, Wako Pure Chemical Industries, Ltd., Japan) at a concentration 
of 15 mM, filtered through a 0.2 μm membrane filter (Advantec Co., Japan), then stored at 4℃ 
until use.  The working concentrations were prepared by dilution with ethanol.  Anti HDAC 
1 (dilution 1:1000, #sc-81598), anti Phospho-NF-κB (dilution 1:1000, #sc-136548) and anti 
β-actin (dilution 1:5000, #66009-1-Ig) antibodies were purchased from Santa Cruz 
Biotechnology and Proteintech Group, respectively.  Primary antibodies against Cyclin A2 
(dilution 1:2000, #4656), Cyclin B1 (dilution 1:2000, #4135), Bcl-XL (dilution 1:1000, 
#2764), Mcl-1 (dilution 1:1000, #5453), Caspase-3/6/7/8/9 (dilution 1:1000, 
#9665/9762/12827/9746/9508), Lamin A/C (dilution 1:2000, #4777), PARP (dilution 1:1000, 
#9542), and Phospho-PI3K (dilution 1:1000, #4228) were purchased from Cell Signaling 
Technology, Inc.  Anti mTOR antibody was obtained from BioLegend (dilution 1:2000, 
#659201).  Anti-topoisomerase 1 antibody was provided by Bioss Antibodies (dilution 
1:1000, #bsm-51396M).  Primary antibodies against Bcl-2 (dilution 1:400, #NBP2-34391), 
Bax (dilution 1:400, #NBP2-32809), p53 (dilution 1:400, #NBP2-44982), Cyclin D1 (dilution 
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1:400, #NBP2-32840) and Akt1 p Ser473 (dilution 1:250, #NB100-56749) were purchased 
from Novus Biologicals, LLC.  ERK (0.2 μg/mL, #AF1576), p-ERK(0.1 μg/mL, #AF1018), 
JNK(0.2 μg/mL, #AF1387), p-JNK(0.5 μg/mL, #AF1205), p38(0.5 μg/mL, #AF8691) and 
p-p38(1 μg/mL, #MAB8691) were provided by R&D Systems, Inc.  All other reagents were 
of the highest quality available from commercial vendors. 
1.2.2 Cell culture 
Human leukemic Jurkat T-cells were purchased from ATCC and cultured in RPMI 1640 
medium containing 10% FBS, 100,000 IU/L penicillin G sodium salt and 100 mg/L 
streptomycin sulfate, and maintained as cell suspension at 37℃ in a humidified atmosphere of 
5% CO2.   
1.2.3 Cell viability measured by WST-8 assay 
Jurkat T-cells (1.5×10
5
 cells/mL) per well were seeded into 96-cell plates, and TET or 
CEP was subsequently added into the corresponding wells to adjust the final concentrations of 
3, 5, 10 and 15 μM, respectively.  The cells were incubated with ethanol or DMSO as a 
control.  After 48 h incubation, 10 μL of WST-8 solution was added to each well, followed 
by additional incubation for 3 h at 37℃.  The optical density value was measured at 450 nm 
absorbance (ref. 650 nm).  The cell viability rate was calculated by 
(Test-Blank)/(Control-Blank)×100%. 
1.2.4 Hoechst 33342 fluorescent staining 
In order to observe the influence of drugs on the morphology of Jurkat T cells, cells were 
treated with TET or CEP for 48 h and then harvested to stain with Hoechest 33342 (#17535, 
AAT Bioquest, Inc, CA, USA).  Briefly, after collection, the cells were fixed with 4% 
paraformaldehyde, followed with phosphate buffered saline (PBS) washing.  Then, the cells 
were incubated with Hoechst 33342 for 10 min at room temperature.  The images of nuclear 
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alteration-related apoptosis were captured with a fluorescence microscope (Biozero BZ-8000 
Series, Keyence, Japan). 
1.2.5 Assessment of apoptosis 
Jurkat cells were seeded in 24-well plates and treated with serial concentrations of TET 
or CEP (0.3, 3, 5, 10 and 15 μM).  Wells containing cell suspension treated by 10 nM of 
CPT were set up as positive control for apoptotic cells.  After 48 h incubation at 37℃, cells 
were harvested and washed by PBS twice.  Apoptotic rates were evaluated by using FITC 
Annexin V Apoptosis Detection Kit (BD Pharmingen
TM
).  The cells were subsequently 

















) cells, respectively, by using a flow 
cytometer (FACSCanto™ II, BD Biosciences, CA, US). 
1.2.6 Cell cycle analysis 
Jurkat T cells were seeded in 6-well plates and incubated in RPMI 1640 medium 
containing blank solvent, CPT (10 nM), CEP (5, 10 and 15 μM) and TET (5, 10 and 15 μM) 
for 48 h, respectively.  Then, the cells were harvested and washed with PBS, and 
subsequently fixed in 70% ethanol at 4℃ for 1 h, and stained with propidium iodide (PI, 50 
μg/mL, #P4864, Sigma Chemical Co.) in the presence of RNase A (0.25 mg/mL, #R5500, 
Sigma Chemical Co.).  DNA content of cells was determined by flow cytometry 
(FACSCanto™ II, BD Biosciences, CA, US).  Data were analyzed by ModFit LT
TM
 
(Version 3.1, Verity Software House, Topsham, ME, USA) 
1.2.7 Western blot analysis 
Cytoplasmic and nuclear proteins were extracted using the Thermo Scientific NE-PER 
Nuclear and Cytoplasmic Extraction Reagents (Pierce Biotechnology, Rockford, IL, USA) 
according to manufacturer’s instruction.  Whole cell protein was extracted by 
radioimmunoprecipitation assay buffer (RIPA) containing Protease and Phosphatase Inhibitor 
(#A32961, Thermo Scientific).  Protein concentration was quantified by Pierce BCA Protein 
11 
Assay Kit (Thermo Scientific).  The cell extracts were subsequently separated by 
SDS-polyacrylamide gel electrophoresis and then electrotransferred to hydrophobic 
polyvinylidene fluoride membrane (Immobilon-P; Merck Millipore, Darmstadt, Germany).  
The membranes were blocked with 5% skimmed milk for 1 h, and subsequently washed with 
Tris-buffered saline/0.1% Tween-20 (TBST).  Then, the membranes were incubated with 
primary antibodies against individual proteins overnight at 4℃.  After triple washing with 
TBST, the membranes were continued to incubate with secondary antibody (Anti-mouse IgG, 
HRP-linked, #7076, Cell Signaling Technology, Inc.) at a dilution of 1:1000 at room 
temperature for 1 h.  After triple washing with TBST, the signals were detected with an ECL 
or ECL Prime Western Blotting detection kit (#RPN2109 and RPN2232, GE Healthcare) in a 
luminescent image analyzer (Fujifilm; LAS-3000; Fujifilm, Tokyo, Japan).  The images 
were then quantitatively analyzed by ImageJ software (version 1.52e, National Institutes of 
Health, USA; http://imagej.nih.gov/ij). 
1.2.8 Statistical analysis 
Differences in the percentages of viable cells, early or late apoptotic cells, and cells in 
cell-cycle phases were analyzed with Bonferroni Multiple Comparison Tests.  Statistical 
analyses for the expression of several proteins were performed using Dunnett's Multiple 
Comparison Test.  These analyses were processed using GraphPad PRISM 5.0 (GraphPad 
Software Inc., San Diego, CA).  In each case, two-sided P values <0.05 were considered to 
be significant. 
1.3 RESULTS 
1.3.1 TET and CEP inhibit the proliferation of Jurkat T cells and change the cell 
morphology 
To investigate the cytotoxicity of TET and CEP against glucocorticoid resistant human 
leukemia cells, Jurkat T cells were exposed to serial concentrations of TET and CEP (3, 5, 10 
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Camptothecin (CPT) (D) 
and 15 μM) and the cell viability was evaluated (Fig. 1-1B).  TET and CEP decreased the 
number of viable Jurkat cells significantly in a dose- and time-dependent manner.  The cell 
number decreased obviously by 10 and 15 μM TET or CEP compared with control group, as 
estimated by Hoeckst 33342 staining (Fig. 1-1C).  Images from the fluorescence microscope 
also showed that 10 nM of CPT used as a positive drug, 10 and 15 μM of TET and CEP 
largely changed the cell morphology with abnormal nuclear of karyorrhexis, chromatin 






















Fig. 1-1  Effects of tetrandrine (TET) and cepharanthine (CEP) on the viability of 
Jurkat T cells.  (A) Chemical structures of TET and CEP.  (B) Jurkat T cells were treated 
with various concentrations (3, 5, 10, 15 μM) of TET (left) or CEP (right) for 24 h (○), 48 h 
(□) and 72 h (△), respectively, and the cell viability was assessed by WST-8 assay.  All of 
the data were expressed as the mean ± S.E.M. (n=3).  Asterisks indicate significant 






P<0.001).  (C) Morphologic change of nuclei in drug-treated Jurkat T cells.  Cells were 
incubated with drugs for 48 h followed by Hoechst 33342 staining.  Camptothecin (CPT) 
group was set up as a positive control.  Representative result of three independent 
experiments was shown.  Abnormal nuclei were indicated by red arrows. (D) Chemical 
structure of CPT. 
1.3.2 TET and CEP induce apoptosis in Jurkat T cells 
To explore whether apoptosis was involved in the cytotoxicity of TET and CEP, 
Annexin V-FITC/PI dual staining assay was performed.  Typical dot-plot diagrams were 













Fig. 1-2  Tetrandrine (TET) and cepharanthine (CEP) induce apoptosis of Jurkat T 
cells.  (A) A dot-plot analysis of Jurkat T cells treated with TET or CEP.  Cells were treated 
with TET or CEP and stained with Annexin V/PI, followed with detection by flow cytometer.  
Camptothecin (CPT) group was set up as a positive control.  Cells were classified into four 
groups based on different quadrants: viable cells (Q3-1), early apoptotic cells (Q4-1), late 
apoptotic cells (Q2-1) and necrotic cells (Q1-1).  (B) Viable cells decreased by treatment 
with TET or CEP in a dose-dependent manner.  Early apoptosis (C) and late apoptosis (D) 






P<0.001).  Data 
represented the mean ± S.E.M. of three independent experiments. 
Comparing with control group, the percentage of viable cells treated by 10 nM CPT was 42.1 
± 4.4% (mean ± SD, P<0.05, Fig. 1-2B).  Both TET and CEP inhibited the cell growth 
dose-dependently.  15 μM of TET and CEP showed the strongest cytotoxic effects, and the 
mean ± SD values of viable cells were 8.4 ± 6.9 and 7.4 ± 2.4%, respectively (P<0.001, Fig. 
1-2B).  Consequently, the percentages of the early and the late apoptotic cells increased 
significantly after treating with 10 nM CPT or higher doses of TET and CEP (Fig. 1-2C-D). 
1.3.3 TET and CEP regulate the expression of proteins related to caspase cascades 
To furtherly investigate the mechanism underlying the TET or CEP-induced apoptosis, 
the expressions of proteins related to caspase cascades were examined.  Complicated 
regulation networks were divided into apoptotic markers and anti-apoptotic factors. 
Apoptotic markers such as caspase-3/6/8/9, p53 and Bax were upregulated by TET or 
CEP (Fig. 1-3A-I).  As shown in Fig. 1-3A, the expression levels of caspase-3 significantly 
increased following treatment with 10 and 15 μM TET (P<0.01).  Meanwhile, TET and CEP 
tended to increase the expression of caspase-8 dose-dependently (Fig. 1-3D), and 15 μM of 
TET showed a significant up-regulation (P<0.05).  A similar increasing tendency was 
observed in the expressions of caspase-6 and caspase-9 after the cells were exposed to TET or 
CEP (Fig. 1-3B and E).  However, the drug treatment seemed to show little influence on the 
expression of caspase-7 (Fig. 1-3C).  CPT at 10 nM did not upregulate the expression of 
caspase-3/6/7/8/9, whereas CPT activated PARP and induced the formation of cleavage PARP 
(89 kDa), which leading to a significant downregulation of full length PARP (Fig. 1-3F).  15 
15 
μM of CEP also downregulated the expression of full length PARP significantly (P<0.05), but 
the cleavage type was not observed (Fig. 1-3F). Whereas, the effects of TET on full length 
PARP were not statistically significant (Fig. 1-3F).  As shown in Fig. 3G and I, Lamin A-C 
and Bax were influenced by the treatment of TET or CEP, and 10 μM of TET maximally 
increased the expression levels of these two pro-apoptotic proteins significantly (P<0.05, Fig. 
1-3G and I).  Furthermore, CEP treatment stimulated the expression of p53 in a 
dose-dependent manner, and 15 μM of CEP significantly increased the amount of p53 
(P<0.05, Fig. 1-3H). TET at 5-15 μM tended to stimulate the expression of p53, though the 
effects were not statistically significantly (Fig. 1-3H).   
Paradoxically, anti-apoptotic factors, such as Bcl-2, Mcl-1 and p-NF-κB, were also 
enhanced by the treatment with CPT, TET and CEP (Fig. 1-4A-D).  As shown in Fig. 1-4A, 
TET or CEP dose-dependently increased the expression of Bcl-2, and 15 μM of TET showed 
a significant increase in the amount of this protein (P<0.05).  Meanwhile, both TET and CEP 
largely upregulated the expression levels of Mcl-1 and p-NF-κB significantly in a 
dose-dependent manner (Fig. 1-4C and D).  None of the three agents changed the 

















Fig. 1-3  Effects of tetrandrine (TET) and cepharanthine (CEP) on the expression levels 
of pro-apoptotic proteins in caspase cascades.  Jurkat T cells were treated with different 
concentrations of TET or CEP (5, 10 and 15 μM) and camptothecin (CPT, 10 nM) for 72 h.  
The cell lysates were examined by Western blot.  More than three independent experiments 
were carried out and representative results were shown.  β-actin was used as internal control.  






















Fig. 1-4  Effects of tetrandrine (TET) and cepharanthine (CEP) on the expression levels 
of anti-apoptotic proteins in caspase cascades.  Jurkat T cells were treated with different 
concentrations of TET or CEP (5, 10 and 15 μM) and camptothecin (CPT, 10 nM) for 72 h.  
The cell lysates were examined by Western blot.  More than three independent experiments 
were carried out and representative results were shown.  β-actin was used as internal control.  









Fig. 1-5  Tetrandrine (TET) and 
cepharanthine (CEP) triggers cell 
cycle in Jurkat T cells.   
(A)  Cells were treated with serial 
concentration of TET and CEP (5, 
10 and 15 μM) for 48 h, 
respectively.  10 nM of 
camptothecin (CPT) was used as a 
positive control.  The peaks marked 
in the figure represent G0/G1, S and 
G2/M phases in the cell cycle, 
respectively.   
 
 
(B) Percentages of cell numbers in 
the cell cycle after 48 h of the agent 
treatment.  All data were expressed 
as the mean ± S.E.M. of three 
independent experiments. 
Asterisks indicate significant 
differences between the control and 







1.3.4 TET and CEP trigger the cell cycle arrest in Jurkat T cells 
To evaluate whether TET or CEP mediated inhibition of cell growth correlated with cell 
cycle arrest, Jurkat T cells were treated with serial concentrations of TET or CEP (5, 10 and 
15 μM).  As shown in Fig. 1-5A-B, 10 nM of CPT as a positive control, largely increased 
cell population at S phase (P<0.001), followed with a significant decrease of cell population 
at G0/G1 phase (P<0.001).  Interestingly, TET or CEP showed similar results that they 
triggered cell cycle arrest and leaded the cell growth to stop at S phase in a dose-dependent 
manner, and thus decreasing the percentage of cells at G0/G1 phase.  None of these three 




















1.3.5 TET and CEP regulate the expression of cell cycle-related proteins 
We continued to examine the influences of TET and CEP on cell cycle-related proteins.  
As shown in Fig. 1-6B, 10 nM of CPT significantly increased the expression level of cyclin 
B1 (P<0.01), and TET or CEP showed the similar regulation effect in a dose-dependent 
manner.  All of these three drugs enhanced the expression of cyclin A2, and 15 μM of TET 
showed the strongest efficacy (P<0.05, Fig. 1-6A).  In contrast, cyclin D1 protein expression 
was effectively downregulated by TET or CEP (Fig. 1-6C). 
1.3.6 TET and CEP activate MAPK 
MAPK activation maintains the proliferation of T cells.  To investigate the molecular 
basis for the effects of TET and CEP on Jurkat cell growth, I examined the influence of TET 
or CEP on MAPK activation.  As shown in Fig 1-7A, both TET and CEP apparently 
stimulated the phosphorylation of p38 in a dose-dependent manner.  15 μM of CEP changed 
the ratio of p-p38 and p38 significantly (P<0.05).  As shown in Fig. 1-7B, 10 nM of CPT 
significantly increased the expression of p-JNK (P<0.05), and TET or CEP also tended to 
activate the p-JNK dose-dependently, though the effects were not significant.  However, 
none of these three drugs significantly influenced the expression of p-ERK (Fig. 1-7C). 
1.3.7 TET and CEP modify PI3K/Akt/mTOR signaling pathway 
To further investigate the molecular mechanism underlying the inhibitory effects of TET 
and CEP on cell survival and growth in the Jurkat T cells, I evaluated the effect of TET or 
CEP on PI3K/Akt/mTOR signaling pathway.  As shown in Fig. 1-8A, 10 nM of CPT 
inhibited the expression of p-PI3K significantly (P<0.05).  Similarly, both TET and CEP 
appeared to decrease the p-PI3K expression dose-dependently.  All of these three agents 
largely downregulated the expression of mTOR, and TET or CEP showed the inhibitory effect 
in a dose-dependent manner (Fig. 1-8C).  However, CPT and TET or CEP paradoxically 
increased the expression of p-Akt1, and the upregulating effects of 10 and 15 μM TET were 








Fig. 1-6  Effects of tetrandrine (TET) and cepharanthine (CEP) on cell cycle regulators in Jurkat T cells.  Cells were treated with 
different concentrations of TET or CEP (5, 10 and 15 μM) and camptothecin (CPT, 10 nM) for 72 h.  The cell lysates were examined by 
Western blot.  More than three independent experiments were carried out, and representative results were shown.  β-actin was used as 













Fig. 1-8  Effects of tetrandrine (TET) and cepharanthine (CEP) on the expression levels of proteins in the PI3K/Akt/mTOR 
signaling pathway.  Cells were treated with different concentrations of TET or CEP (5, 10 and 15 μM) and camptothecin (CPT, 10 nM) 
for 72 h.  Western blot assays were carried out to examine the effects of TET or CEP on the expressions of key proteins p-PI3K (A), 
p-Akt (B) and mTOR (C).  β-actin was used as internal control.  All images are representative of three independent experiments.  








Fig. 1-7  Effects of 
tetrandrine (TET) and 
cepharanthine (CEP) on the 
expression levels of 
mitogen-activated protein 
kinase proteins.   
Cells were treated with 
different concentrations of 
TET or CEP (5, 10 and 15 
μM) and camptothecin (CPT, 
10 nM) for 24 h.  The cell 
lysates were examined by 
Western blot.  More than 
three independent experiments 
were carried out and 
representative results were 
shown.  β-actin was used as 
internal control.  Asterisks 
indicate significant differences 
between the control and the 

































1.3.8 Synergic effect of steroid combined with TET or CEP on Jurkat T cell proliferation 
Glucocorticoids (GCs) are among the first drug classes used in the treatment of patients 
with ALL, and are still essential components of treatment.  Then, I examined the inhibitory 
effects of the combination of GC and TET or CEP.  Methylprednisolone (MP) is one of the 






Fig. 1-9  Chemical structure of methylprednisolone (MP) 
As shown in Fig. 1-10, low concentration of MP potentiated the anti-T-ALL effects of 
TET or CEP.  Although MP alone showed little cytotoxicity on Jurkat T cells, ng/mL grade 
of MP decreased the IC50 values of TET and CEP dose-dependently and significantly.  The 
Combination Index of MP with TET or CEP was lower than 1, indicating that the 













Fig. 1-10  Methylprednisolone (MP) potentiates inhibitory effect of tetrandrine (TET) 
or cepharanthine (CEP) on Jurkat T cells.  Jurkat T cells were treated with various 
concentrations (3, 5, 10 μM) of TET (A-C) or CEP (D-F) with or without methylprednisolone 
(MP) for 48 h, and the cell viability was assessed by WST-8 assay.  IC50 values of TET (B) 
and CEP (E) were calculated by GraphPad Prism 5.0.  The Combination Index for the effect 
of TET (C) or CEP (F) combined with MP was calculated using CompuSyn software.  All of 
the data were expressed as the mean ± S.E.M. (n=4).  Asterisks indicate significant 








Despite of the treatment by high-dose antileukemic drugs and improved supportive care, 
the prognosis of patients with glucocorticoid resistant T‑ALL who fail to obtain a complete 
hematological remission or those whose disease relapses after a transient initial response 
remains poor [4, 5].  Moreover, these aggressive treatment regimens are often associated 
with severe acute toxicities and long-term side effects, especially, for pediatric T-ALL [7].  
Faced with these clinical challenges, it is urgent to develop more effective and less toxic drugs 
for T-ALL.   
Bisbenzylisoquinoline alkaloids TET and CEP (Fig. 1-1A) isolated from traditional herbs 
are commercially distributed in China and Japan for more than 20 years respectively, which 
certifies the safety of these two compounds.  Meanwhile, with the advantage of high 
tolerance, TET has been registered as CBT-1® in USA and was studied in the clinical trials in 
association with doxorubicin for treating patients with advanced solid tumors [33].  Recent 
numerous molecular investigations for the efficacy of TET and CEP firmly support that they 
would be suitable candidates for anti-cancer drugs [34-37].  However, fewer studies are 
designed to examine the underlying action mechanisms of TET or CEP for their anti-T-ALL 
effects.  Therefore, the present study was performed to investigate the cytotoxic effects of 
TET and CEP by using the steroid resistant human leukemia Jurkat T cell line. 
The WST-8 assay data suggested that TET or CEP inhibited the proliferation of Jurkat T 
cells (Fig. 1-1B), and the inhibitory tendency was consistent with the data obtained by 
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Annexin‑V and PI staining (Fig. 1-2B).  Images obtained from fluorescence microscopy 
revealed that the cell morphology was largely changed to show karyorrhexis, chromatin 
condensation and fragmentation (Fig. 1-1C), which indicated that cell apoptosis seriously 
occurred.  This finding was also certified by the results of apoptosis analysis shown in Fig. 
1-2C and D.  Both TET and CEP showed cytotoxic effect on Jurkat T cells by inducing 
apoptosis, which were consistent with the observations of previous reports [38, 39].   
Caspase cascades are pivotal components of apoptosis.  To date, two types of caspases, 
the initiator caspase and effector/executioner caspase, have been defined [40].  I showed that 
TET or CEP not only upregulated the expression of initiator caspases such as caspase-8 and 9 
(Fig. 1-3D and E), but also increased the expression of effector caspases such as caspase-3 
and 6 (Fig. 1-3A and B).  Moreover, Jianghong Wu et al. reported that 24 h treatment with 
10 μM CEP activated the caspase-3/8/9, which leads to increase in cleaved products of these 
caspases in Jurkat T cells [39].  After Jurkat T cells were treated with 30 μM TET for 12 h, 
the amount of cleaved caspase-3 in these cells was reported to increase significantly [41].  
All these findings suggested that caspases contributed to the apoptotic effect of TET or CEP.  
However, TET or CEP seemed to show little effect on caspase-7, another important effector 
caspase, suggesting that caspase-7 was not the main target of TET or CEP (Fig. 1-3C).   
PARP, which is known to be cleaved and inactivated by caspase-3 and 7, converts DNA 
breaks into intracellular signals, which activate DNA repair programs or cell death options 
and plays a pivotal role particularly in the maintenance of genomic DNA stability and 
regulation of apoptosis [42].  Cleavage of PARP facilitates cellular disassembly and serves 
as a marker of cells undergoing apoptosis [43].  Here, I showed that CPT induced the 
cleavage of PARP, resulting in a significant decrease of full length PARP (Fig. 1-3F).  TET 
or CEP downregulated the expression amount of full length PARP with little influence on the 
cleavage of PARP (Fig. 1-3F).  The above different phenomenon would be related to the 
different activities of CPT, TET and CEP on caspase cascades, since CPT had almost no 
effects on the expression of caspase-3/6/7/8/9 (Fig. 1-3A-E).  Lamins, which will be 
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activated by caspase-6, are nuclear membrane structural components, and are important in 
maintaining normal cell functions such as cell cycle control, DNA replication, chromatin 
organization and apoptosis [44-46].  TET or CEP upregulated the expression of lamin A/C, 
which was consistent with the largely changed morphology of Jurkat T cells treated by these 
agents (Fig. 1-1C).  DNA damage leads to high response of tumor suppressor p53 [47].  
Subsequently, p53 induces a large number of apoptotic genes that are associated with various 
steps of apoptosis [48].  The present study revealed that both TET and CEP largely increased 
the expression amounts of p53, whereas CPT showed a slight effect (Fig. 1-3H).  Bax is one 
of the members of Bcl-2 family, which induces apoptosis through mitochondrial stress [49-51].  
TET or CEP strongly stimulated Bax expression at 5 and 10 μM, while they decreased the 
expression at 15 μM (Fig. 1-3I).  Excessive stimulation of p-Akt1 by 15 μM TET or CEP, as 
shown in Fig. 8B, may account for the paradoxical results, since Akt inhibits a conformational 
change in the pro-apoptotic Bax protein and its translocation into mitochondria [52].   
However, all of these three agents seem to enhance the expression of survival protein, 
p-NF-κB, and anti-apoptotic proteins of Bcl-2 family such as Bcl-2 and Mcl-1 (Fig. 1-4A-D).  
Activation of NF-κB is usually considered to maintain the survival of cancer cells.  Indeed, 
the activation of NF-κB by TNF-α, ionizing radiation, or daunorubicin was found to protect 
from cancer cell killing [53, 54].  Actually, the nature of the signals elicited by the respective 
death inducers determines whether NF-κB induction leads to apoptosis or survival [55].  In T 
lymphocytes, DNA damaging agents were reported to induce expression of Fas ligand and 
subsequent apoptosis by activation of NF-κB [56].  Whereas, I certified that NF-κB inhibitor, 
BAY 11-7082, potentiated, but did not eliminate, the cytotoxic effects of TET or CEP on 
Jurkat T cells (data not shown).  Thus, activation of NF-κB is an adverse factor 
counteracting to the anti-TALL effect of TET or CEP.  The anti-apoptotic state in leukemic 
cells contributes to an alternative explanation for refractory ALL [4].  Over expression of 
Bcl-2 was observed in childhood ALL, which appeared to enhance the ability of lymphoblasts 
to survive without essential trophic factors, and a Bcl-2 inhibitor ABT-199 suppresses TLX3- 
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or HOXA-positive primary T-ALLs sensitively [57, 58].  Combination of TET or CEP and 
ABT-199 would be meaningful to overcome the anti-apoptotic effects of higher Bcl-2 
expression induced by TET or CEP, although Bcl-2 did not appear to affect prognosis in ALL 
[57, 59].  Mcl-1 is another crucial pro-survival factor, and overexpressing Mcl-1 may relate 
to chemo-resistance in leukemia cells [60].  Protein kinase inhibitor H89 was reported to 
show a synergic anti-cancer effect with TET by modulating Mcl-1 expression [61]. 
Development of T-ALL is also known to be resulted from the loss of cell cycle control 
[5].  Cyclin D overexpression is commonly seen in human T-ALL, and specific cyclin D 
expression is associated with distinct T-ALL subsets [62].  Thus, as like the most common 
human tumors, cell cycle arrest would be an important way to regulate T-ALL cell growth and 
proliferation [63].  In the present study, I found that all of the three agents largely arrested 
the cell cycle progression at S phase in a dose-dependent manner, following with a significant 
decrease of cell population at G0/G1 phase (Fig. 1-5A-B).  S phase is a crucial event in the 
cell cycle that allows proper replication of DNA without accumulating genetic abnormalities 
[64].  Topoisomerase Ⅰ relaxes the DNA supercoil form during the DNA replication process, 
and I showed that CPT significantly inhibited the expression of topoisomerase Ⅰ in Jurkat T 
cells (data not shown).  My present data suggested that CPT caused DNA damage and 
activated the cell cycle checkpoint with a cell cycle arrest at S phase, as has been suggested 
by other researchers [65].  In contrast, TET or CEP, sharing similar arresting-effect on cell 
cycle with that of CPT, did not influence the expression of topoisomerase Ⅰ in Jurkat T cell 
nucleus (data not shown).  As we have known, transition from one cell cycle phase to 
another occurs in an orderly fashion and is regulated by different cellular proteins, such as 
cyclin A/B/D [66].  Further investigation revealed that both CPT and TET or CEP 
upregulated the expressions of cyclin A2 and B1 but downregulated the expression of cyclin 
D1, which might contribute to their similar effect on cell cycle arrest (Fig. 1-6A-C).    
Activated mitogen-activated protein kinase (MAPK) has been reported to play a major 
role in promoting and maintaining T lymphocyte populations [67, 68].  For example, ERK2 
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is required for the proliferation of CD8 T cells activated in the absence of co-stimulation [69].  
Unlike the normal T cells, activated MAPK may contribute to the apoptotic process of 
malignant Jurkat T cells.  As shown in Fig. 1-7A, p38 was activated by the treatment with 
TET or CEP apparently and dose-dependently, which was accompanied by the induction of 
apoptosis.  This finding was consistent with that of the previous study [70].  Comparing 
with TET or CEP, 10 nM of CPT strongly stimulated the phosphorylation of JNK (Fig. 1-7B).  
It was reported that JNK mediates phosphorylation of anti-apoptotic proteins Bcl-2/Bcl-xL, 
which changes the mitochondrial membrane potential to release cytochrome c.  Then, 
caspase-9 is activated following with caspase-3 activation.  Finally, JNK sensitizes cancer 
cells to genotoxic stress-induced cell death [71].  However, all of the three agents rarely 
influenced on the activation of ERK (Fig. 1-7C). 
PI3K/Akt/mTOR signaling pathway controls multiple cellular responses including 
metabolic regulation, cell growth, and survival [7].  In human T-ALL, constitutive activation 
of the PI3K/Akt/mTOR signal transduction pathway is achieved by deletions or mutations 
targeting PTEN in approximately 15% of cases [7, 72, 73].  Targeting the PI3K/Akt/mTOR 
signaling pathway would be another possible option to discover the leading compound for the 
treatment of relapsed or refractory T-ALL.  My data showed that CPT, TET, and CEP 
inhibited the expression amounts of p-PI3K and mTOR, whereas the treatment by these 
agents resulted in high expression of p-Akt1 paradoxically (Fig. 1-8A-C).  Although Akt 
was viewed as a major downstream effector of PI3K at least in physiological processes, 
several studies suggested that PI3K and Akt act independently in cancers [74].  While PI3K 
is a major regulator of Akt activation in response to a variety of ligands, recent studies 
highlighted that diverse groups of tyrosine (Ack1/TNK2, Src, PTK6) and serine/threonine 
(TBK1, IKBKE, DNAPKcs) kinases also activate Akt directly to promote growth, 
proliferation and oncogenic transformation [75].  Thus, TET and CEP regulated the 
expressions of p-PI3K and mTOR in an independent way on Akt.  Future studies are needed 
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to further characterize the role of TET and CEP on the complex relationship between PI3K 
and AKT in cancer. 
TET and CEP share the same bisbenzylisoquinoline skeletons and thus both of them 
show similar efficacy on the above multiple targets.  Whereas, the steric configurations and 
substituent groups of TET and CEP are largely different.  Subsequently, I observed different 
influences of TET and CEP on the signal proteins caspase-3/8, cyclin A2/B1 and mTOR.  
However, I still can preliminarily infer that the steric configuration of the two 
benzylisouinoline units will not affect the cytotoxicity of bisbenzylisoquinoline alkaloid on 
glucocorticoid resistant human leukemia Jurkat T cells, because I did not observe any 
contradictory effects of TET and CEP, although they share the opposite steric configurations.  
The structure-activity relationship of bisbenzylisoquinoline skeletons deserves to be explored 
comprehensively in the future.   
There are still a lot of other important questions which remain to be answered.  As I 
have mentioned, several different molecular mechanisms contribute to GC resistance.  
Indeed, many kinds of GC resistant T-ALL cell lines such as Jurkat, MOLT-4 and CEM 
MTX-R3 cells have been known.  My examination in this Chapter limited to the cytotoxic 
effects of TET and CEP in Jurkat T cells only, and thus how TET or CEP influences the 
viability of other GC resistant T-ALL cells is remained to be studied in the future.  In Japan, 
CEP is usually used for the treatment of leukocytopenia caused by radiation, which seems to 
be paradoxical with my findings.  Therefore, the influence of radiation on cell physiology 
and molecular mechanisms of the therapeutic efficacy of CEP on leukocytopenia are the next 
problems to be elucidated.  Cytotoxicity of TET and CEP on normal cells is also necessary to 
be addressed in the future.   
Probably of more importance is the synergic effect of the combination of MP and TET or 
CEP, as shown in Fig. 1-10.  As I mentioned above, activation of NF-κB is an adverse factor 
counteracting with the anti-TALL effect of TET or CEP.  NF-κB inhibitor, BAY 11-7082 
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potentiates the cytotoxic effects of TET or CEP on Jurkat T cells (data not shown).  
Therefore, inhibitory effect of MP on NF-B may help us to explain this synergic effect of the 
combination.  However, other anti-leukemic drugs such as methotrexate, vincristine, 
THP-adriamycin, cyclophosphamide, L-asparaginase, cytarabine and mercaptopurine are 
inevitably recommended to the patients with T-ALL according to the Japanese Clinical 
Guidelines for Childhood Leukemia and Lymphoma in 2016 [6].  How does TET or CEP 
influence the pharmacodynamics of the above-mentioned chemotherapeutic drugs?  This 
point remains to be disclosed in the future.   
Because a considerable number of patients with chronic inflammatory or autoimmune 
diseases show a poor or absent response even to high doses of GCs, the GC resistance or 
insensitivity represents an important barrier for the effective treatment of these patients [14].  
Therefore, combination of MP and TET or CEP could be a new therapeutic approach for GC 
resistant patients.  In Chapters 2 and 3, I continued to examine the synergic effects and the 
possible mechanisms of these combinations on human T cells.   
1.5 CONCLUSION 
Taken together, the data of this chapter can conclude that bisbenzylisoquinoline alkaloids 
represented by TET and CEP show cytotoxic effect on GC resistant human leukemia Jurkat T 
cells by inducing apoptosis through caspase cascade regulation, cell cycle arrest, MAPK 
activation and PI3K/Akt/mTOR signal modification.  The combination of GC and TET or 





Tetrandrine potentiates the steroid pharmacodynamics in 
mitogen-activated peripheral blood mononuclear cells of healthy subjects  
2.1 INTRODUCTION 
As mentioned in Chapter 1, Boui derived bisbenzylisoquinoline alkaloid TET showed 
significant inhibitory effect on a GC resistant human Jurkat T cell line.  Moreover, synergic 
effect of MP and TET or CEP was observed.  It is highly possible to use the combination of 
MP and TET or CEP to enhance the immunosuppressive effect of GC to overcome GC 
resistance.   
Lots of our studies have certified individual variations of GC efficacy in patients of 
bronchial asthma [76], minimal change nephrotic syndrome [77], ulcerative colitis [78] and 
other kinds of inflammatory or immunological diseases [15].  Since a considerable number 
of patients with these chronic inflammatory or autoimmune diseases show a poor or absent 
response even to high doses of GCs, the GC resistance or insensitivity represents an important 
barrier for the effective treatment of these patients [14].  New therapeutic approaches to 
increase the GC sensitivity are thus urgent to be developed for GC resistant patients. 
Then, in this Chapter, the synergic immunosuppressive effect of TET with MP was 
investigated by using the human peripheral blood mononuclear cell (PBMC) culture system, 
and I also explored its possible action mechanisms with focus on P-glycoprotein, MAPK, and 
GC receptor (GR) signaling pathways. 
2.2 MATERIALS AND METHODS 
2.2.1 Drugs and reagents 
RPMI1640 and FBS were purchased from Gibco BRL (Grand Island, NY, USA).  
Concanavalin A (Con A) was obtained from Seikagaku Kogyo Co., Tokyo, Japan. Tetrandrine 
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(purity: more than 98%) and verapamil were purchased from Sigma Aldrich (St. Louis. Mo., 
USA).  TET was dissolved in ethanol at a concentration of 15 mM, filtered through a 0.2 μm 
membrane filter (Advantec Co., Japan), and diluted to 150 μM stock solution in ethanol and 
then stored at 4℃ until use.  The working concentrations were prepared by dilution with 
ethanol. MP was provided from Sigma Aldrich (St. Louis. Mo., USA), dissolved in ethanol 
and then stored at 4℃ until use.  The cell proliferation WST-8 assay kits were obtained from 
Dojindo Molecular Technologies, Inc., Japan.  BD Cytometric Bead Array (CBA) Human 
Th1/ Th2/Th17 Cytokine Kit, Alexa Fluor
®
 488 Mouse anti-human Foxp3, FITC mouse 
anti-human CD4, and APC Mouse Anti-Human CD8 and CD25 were obtained from BD 
Biosciences, San Jose, CA, USA.  GR antibody (G-5) was provided by Santa Cruz 
Biotechnology, INC (dilution 1:1000, # sc-393232).  β-actin was purchased from Proteintech 
Group (dilution 1:5000, # 66009-1-Ig). All other reagents were of the highest quality available 
from commercial vendors. 
2.2.2 Subjects 
The present study was carried out in accordance with The Code of Ethics of the World 
Medical Association (Declaration of Helsinki).  The study was approved by the Ethical 
Committee of Tokyo University of Pharmacy and Life Sciences and written informed consent 
was obtained from all healthy subjects included in the study.  The study included 9 healthy 
subjects (4 males and 5 females with a mean age of 34.4 years).  These subjects had neither a 
history of immunological disorders nor a history of taking immunosuppressive drugs 
including steroids. 
2.2.3 Isolation of PBMCs and evaluation of drug effects in vitro 
Twenty milliliters of venous blood were taken from healthy subjects between 9:00 and 
11:00 in the morning and heparinized.  This 20 mL sample size was the smallest possible to 
examine the effects of MP in the presence or absence of TET.  The heparinized blood was 
loaded on 3 mL of Ficoll-Hypaque (Nakarai Co., Japan), and centrifuged at 1300 ×g for 20 
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min.  PBMCs were separated and suspended with RPMI 1640 medium containing 10% FBS, 
100,000 IU/L penicillin G sodium salt and 100 mg/L streptomycin sulfate to a final density of 
1 × 10
6
 cells/mL.  194 μL of this cell suspension were loaded into wells of a 96-well plate.  
Con A as a T-cell mitogen was added to each well to a final concentration of 5.0 μg/mL.  
Subsequently, 2 μL of an ethanol solution containing MP were added to give final 
concentrations of 0.05, 0.5, 5, and 50 ng/mL.  To examine the additional effect of TET 
combined with MP, 4 μl of an ethanol solution containing TET were subsequently added to 
give final concentrations of 0.3, 3, 30 and 300 nM, respectively.  Six microliters of ethanol 
were added to the control wells.  The plate was incubated for 96 h in 5% CO2 at 37℃.  
After the culture, 10 μL of WST-8 assay reagent solution were added to each well, and the 
plate was incubated for another 3 h.  The optical density value was measured at 450 nm 
absorbance (ref. 650 nm).  PBMC proliferation was calculated by 
(Test-Blank)/(Control-Blank)×100%.  IC50 values of MP were obtained by GraphPad Prism 
5.   
2.2.4 Functional assays for P-glycoprotein 
P-glycoprotein function of PBMCs was measured by Rhodamine (Rh) 123 efflux assay 
using flow cytometry.  In brief, 0.5 mL of the cell suspension containing 1 × 10
6
 cells/mL 
prepared as above were loaded with Rh123 to yield a final concentration of 2 μM and 
incubated for 10 min in 5% CO2 at 37℃.  After the accumulation period of 10 min, the cells 
were washed with ice-cold PBS containing 10% FBS twice to remove Rh123 from the 
medium completely.  Then, Rh123-treated cells were re-suspended in a Rh123-free complete 
media with or without drugs, i.e., TET (3, 30, 300 and 3000 nM), MP (0.5 ng/mL) and 
verapamil (5 μM) at 37℃ for 180 min.  Verapamil was used as a typical P-glycoprotein 
specific competitive inhibitor.  After the efflux period, cells were washed twice with ice-cold 
PBS contained with 10% FBS and were then stained with FITC mouse anti-human CD4 and 
APC Mouse Anti-Human CD8.  After staining, the cells were washed twice and then 
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re-suspended in PBS and kept on ice in the dark until analysis by FACSCanto ™ II (BD 
Biosciences, San Jose, CA).   
2.2.5 Quantification of human cytokines 
PBMCs were incubated for 96 h in the presence of Con A, TET and MP together or 
respectively as described above, and the culture supernatant was stored at −80℃ until 
measurement of cytokine concentrations.  The concentrations of interferon (IFN)-γ, TNF-α, 
IL-2, -4, -6, -10 and -17 in the culture supernatant were measured with beads-array procedures 
using the Human Th1/Th2/Th17 Cytokine Kit, followed by flow cytometry, according to the 
instructions of BD Biosciences (San Jose, CA).  The data were analyzed using BD™ 







 T cell analysis 
PBMCs treated with MP and/or TET in the presence of Con A for 96 h were washed 
twice with PBS.  Subsequently, 10 μL FITC Mouse Anti-Human CD4 and 10 μL APC 
Mouse Anti-Human CD25 (BD Biosciences) were added.  The cell suspensions were 
incubated for 20 min at 37℃ in the dark.  After incubation, the cells were washed with PBS 
and re-suspended with 1 mL of PBS.  Then, 1 mL of 10-fold diluted Human Foxp3 Buffer A 
(BD Biosciences) with distilled water was added, and incubated for 10 min in the dark at the 
room temperature.  The cells were washed with PBS, re-suspended with 0.2 mL of Human 
Foxp3 Buffer B (BD Biosciences) diluted with the 10-fold diluted Human Foxp3 Buffer A, 
and incubated for 30 min in the dark at room temperature.  After incubation, 1 mL of PBS 
was added and centrifuged for 5 min.  The supernatant was removed and the cells were 
washed with PBS.  Then, 10 μL of Alexa Fluor
®
 488 Mouse anti-human Foxp3 (BD 
Biosciences) were added, and the cell suspension was incubated for 30 min at 37℃ in the 
dark. After washing the cells with PBS, 0.4 mL of staining buffer was added to the cell 
suspension, and then analyzed with flow cytometry.  
34 
The data were analyzed with FACSCanto ™ II (BD Biosciences), using BD 
FACSDiva™ software. CD4
+







 cells in the CD4
+
 cell fraction were calculated 
2.2.7 Assessment of phosphorylation of MAPK isoforms 
Phosphorylation of ERK1/2, P38 and JNK as indicative of mitogen-activated protein 
kinase (MAPK) were determined by Cell Lysates ELISA kits (Ray Biotech Inc, USA) 
according to each manufacturer’s instruction.  Briefly, 1.288 ml of 1 × 10
6
 cells/mL PBMC 
suspension were seeded and pre-treated with or without TET (final concentration of 3 or 3000 
nM) for 2h.  Then, 14 μL of an ethanol solution containing MP were added to give a final 
concentration of 0.5 ng/mL.  In order to activate T cells and phosphorylate MAPK in these 
cells, 70 μL of Con A solution was added to yield a final concentration of 21 μg/mL.  
Subsequently, cells were incubated in 5% CO2 at 37℃ for 5 or 15 min.  A control cell 
population was cultured in the medium without drugs. Cells were lysed in 128.8 μL of cell 
lysis buffer, and then microcentrifuged at 4℃.  The supernatants were obtained and diluted 
10 folds.  The cell lysates were incubated with rabbit anti total and phosphorylated P38 
(p-P38), ERK1/2 (p-ERK1/2), or JNK (p-JNK), followed by incubation with HRP-conjugated 
anti-rabbit IgG or streptavidin.  Finally, 3, 3’, 5, 5’–tetramethylbenzidine was added, 
followed by addition of stop solution, and the optical density was read at 450 nm.  The cells 
treated by the drugs for 5 min were used to examine ERK1/2 and P38, and the cells treated for 
15 min were used for JNK analysis. 
2.2.8 MOLT-4 and MOLT-4/DNR cell culture 
Human lymphoblastic leukemia MOLT-4 cells and their daunorubicin resistant 
MOLT-4/DNR T cells, which expressed high amounts of P-glycoprotein [79], were 
maintained in RPMI 1640 medium containing 10% FBS, 100,000 IU/L penicillin G sodium 
salt and 100 mg/L streptomycin sulfate, at 37℃ in a humidified atmosphere of 5% CO2. 
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2.2.9 Western blot analysis 
MOLT-4 and MOLT-4/DNR T cells were treated with TET and MP for 1 h.  
Cytoplasmic and nuclear proteins were extracted using the Thermo Scientific NE-PER 
Nuclear and Cytoplasmic Extraction Reagents (Pierce Biotechnology, Rockford, IL, USA) 
according to manufacturer’s instruction.  Protein concentration was quantified by Pierce 
BCA Protein Assay Kit (Thermo Scientific).  Cytoplasmic and nuclear extracts were 
subsequently separated by SDS-polyacrylamide gel electrophoresis and then 
electrotransferred to hydrophobic polyvinylidene fluoride membrane (Immobilon-P; Merck 
Millipore, Darmstadt, Germany).  The membranes were subsequently blocked with 5% 
skimmed milk for 1 h and washed with Tris-buffered saline/0.1% Tween-20 (TBST).  Then, 
the membranes were incubated with primary antibodies against individual proteins overnight 
at 4℃.  After washing three times with TBST, the membranes were continued to incubate 
with secondary antibody (Anti-mouse IgG, HRP-linked, #7076, Cell Signaling Technology, 
Inc.) at a dilution of 1:1000 at room temperature for 1 h.  After washing three times with 
TBST, the signals were detected with an ECL or ECL Prime Western Blotting detection kit 
(GE Healthcare) in a luminescent image analyzer (Fujifilm; LAS-3000; Fujifilm, Tokyo, 
Japan).  The images were quantitatively analyzed by ImageJ software (version 1.52e, 
National Institutes of Health, USA; http://imagej.nih.gov/ij). 
2.2.10 Statistical analysis 
Differences in the percentages of PBMC proliferations, IC50 values of drugs, Rh 123 
accumulated amounts and relative phosphorylations of MAPK between control and the 
drug-treated cell fractions were analyzed with Bonferroni tests.  Differences in the amounts 
of cytokines produced in the culture medium and the percentages of Treg cells in the CD4
+
 
cell fraction between control and the drug-treated cell fractions were analyzed with Wilcoxon 
matched-pairs signed rank test.  Differences in the expression amounts of GR between the 
control group and the groups treated with serial concentrations of the drug were analyzed with 
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Bonferroni multiple comparison tests.  Statistical analyses for the differences of GR 
expression amounts in MOLT-4 or MOLT-4/DNR cells between the cells treated by MP 
alone and those treated with MP combined with TET were carried out by Mann-Whitney test.  
These analyses were performed with GraphPad PRISM 5.0.  In each case, two-sided P 
values <0.05 were considered to be significant. 
2.3 RESULTS 
2.3.1 Effects of MP combined with TET on mitogen-activated proliferation of PBMCs 
I first examined the effects of MP in the presence or absence of TET on cell proliferation 
of PBMCs activated with a T-cell mitogen, Con A, in vitro.  The PBMCs obtained from 
healthy subjects were cultured in the presence of Con A and serial concentrations of MP with 
or without TET for 96 h, and the proliferative response of the PBMCs was estimated by WST 
assay procedures (Fig. 2-1A).  MP dose-dependently inhibited the PBMC proliferation, and 
TET significantly potentiated the suppressive effects of MP at doses of 0.05 and 0.5 ng/ml as 
shown in Fig. 2-1A (P<0.05).  The mean (S.E.M.) of MP IC50 values was 3.57 (0.61) ng/ml, 
whereas the mean (S.D.) IC50 values of MP combined with 0.3, 3, 30, and 300 nM TET were 
1.02 (0.37), 0.61 (0.15), 1.21 (0.30), and 0.91 (0.45) ng/ml, respectively (Fig. 2-1B).  
However, TET at 0.3 to 300 nM without MP exhibited no or little effect on the Con A 
stimulated proliferation of PBMCs (Fig. 2-1A).  MP at 0.05 and 0.5 ng/ml appeared to be 
suitable to investigate the action mechanism, since the inhibitory ability of MP itself was mild 






Fig. 2-1  Effects of methylprednisolone (MP) in the presence or absence of tetrandrine 
(TET) on proliferation of PBMCs activated with concanavalin A.  Cell proliferation was 
determined by WST-8 assay.  PBMC proliferation (%) was estimated from the formula 
(Test-Blank)/(Control-Blank)×100%.  IC50 values were calculated by GraphPad Prism 5.  
(A) Inhibition of PBMC proliferation by MP combined with TET.  (B) IC50 values of MP in 
the presence or absence of TET.  The data were expressed as means ± S.E.M. Statistical 






P<0.001, as compared to the group treated by MP alone. (n=7) 
2.3.2 Effects of TET combined with MP on P-glycoprotein function of PBMCs 
P-glycoprotein function on PBMCs was characterized by determining the Rh123 
accumulation/efflux capacity.  As shown in Fig. 2-2A, 5 μM of verapamil, a positive 
P-glycoprotein blocker, increased the accumulation of Rh123.  The data indicated that the 
drug decreased the intracellular dye efflux of CD4
+
 T cells, CD8
+
 T cells and lymphocytes 
significantly, and thus inhibited the P-glycoprotein function.  After treatment with TET, the 
Rh123 accumulation also increased significantly by 300 nM and 3 μM of TET (P<0.001, Fig. 
2-2A).  300 nM of TET exhibited similar inhibitory ability to that of 5 μM verapamil.  
However, as shown in Fig. 2-2B, 0.5 ng/mL of MP had little effect on P-glycoprotein function 
of CD4
+
 T cells, CD8
+
 T cells and lymphocytes.  Meanwhile, verapamil or TET in the 










Fig. 2-2  Rhodamine 123 (Rh123) accumulation in PBMCs by tetrandrine (TET).  
PBMCs were incubated with 2 μM Rh123 for 10 min to uptake the fluorescent dye.  
Subsequently, the cells were washed and cultured for 180 min with or without drugs to efflux 
intracellular dye.  (A) Effects of TET as compared with verapamil, the prototype 
P-glycoprotein blocker, on P-glycoprotein function of peripheral lymphocytes.  PBMCs were 
incubated with 3, 30, 300 nM and 3μM of TET for the efflux period, and the Rh123 
accumulation was measured by flow cytometry.  (B) P-glycoprotein inhibitory effect of TET 
in the presence of MP.  Rh123 mean fluorescence intensities were detected by flow 
cytometry analysis, and Rh123 accumulated (%) was calculated by the formula: Dye 
accumulated/Dye uptaken × 100 (%).  The results were expressed as means ± S.E.M.  












P<0.001, as compared to the group treated with MP alone. (n=3) 
2.3.3 Effects of MP combined with TET on cytokine production from mitogen-activated 
PBMCs 
The effects of MP in combination with TET on the production of Th1/Th2/Th17 
cytokines (IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ and IL-17) in culture supernatant of Con 
A-activated PBMCs were examined.  The mean (S.E.M.) concentration of IL-6 and 
TNF-in supernatant of the stimulated PBMCs cultured without drugs were 97.68 (42.98) 
and 161.25 (89.90) pg/ml, respectively.  Both TET and MP showed the similar ability to 
repress these cytokine productions.  TET enhanced the suppressive function of MP on the 
production of these two cytokines (P<0.05, Fig. 2-3).  However, the results of other cytokines 
did not significantly differ between cultures treated with the combination and those treated 












Fig. 2-3  Cytokine concentrations in the supernatant of T-cell mitogen-activated 
PBMCs treated with tetrandrine (TET) and/or methylprednisolone (MP). 
PBMCs were stimulated with concanavalin A (Con A) for 96 h in the absence or presence of 
TET (0.3, 3, 30 and 300 nM) and/or MP (0.05 and 0.5 ng/mL).  Then the culture supernatant 
was analyzed for concentrations of TNF-α and IL-6 using beads-array procedures followed by 
flow cytometry.  Averaged results obtained using PBMCs from 7 healthy subjects were 
shown (± S.E.M.).  Statistical analyses were performed using Wilcoxon matched-pairs 
signed rank tests to analyze the differences between each group. 
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 T cells in mitogen-activated PBMCs cultured in 
the presence or absence of TET and/or MP for 96 h were analyzed with flow cytometry. CD4
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cells were calculated (Fig. 2-4).  TET, MP and 
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 T cells in concanavalin 
A-stimulated PBMCs treated with tetrandrine (TET) and/or methylprednisolone (MP). 
PBMCs were treated with serial concentrations of the drugs for 96 h, and then analyzed with 
flow cytometry, as described in Materials and Methods.  The data were indicated as the mean 
± S.E.M.  Statistically significant changes as compared to PBMCs treated with concanavalin 
A without drugs were not observed using Wilcoxon matched-pairs signed rank tests. (n=3) 
2.3.5 Effect of MP combined with TET on phosphorylation of MAPK isoforms in 
mitogen-activated PBMCs 
The effects of MP in the presence or absence of TET on the activation of cellular 
ERK1/2, P38 and JNK in PBMCs stimulated with Con A were examined (Fig. 2-5).  The 
relative phosphorylation of ERK1/2 and P38 increased by the stimulation with Con A for 5 
min.  MP at 0.5 ng/mL tended to repress the ERK1/2 activity.  Meanwhile, 3 μM of TET 
suppressed ERK1/2 phosphorylation, though the effect was not statistically significant (Fig. 
2-5A).  The synergic inhibitory effect by the combination of MP (0.5 ng/ml) with TET (3 
μM) was observed significantly (P<0.05) when compared with the group treated by MP alone.  
Similarly, the tendency of synergic suppressing effect on P38 was observed by the same 
combination of MP with TET, though the effect was not statistically significant. (Fig. 2-5B).  
On the other hand, Con A did not stimulate significantly the phosphorylation of JNK by 15 






Fig. 2-5  Effect of methylprednisolone (MP) in the presence or absence of tetrandrine 
(TET) on phosphorylation of MAPK isoforms in concanavalin A-activated PBMCs.  
PBMCs were pretreated with TET for 2 h and then incubated with or without concanavalin A 
together with the drugs or the solvents for 5 min.  The phosphorylated MAPK isoforms in 
the PBMC lysates were determined by ELISA using anti-phosphorylated kinase-antibodies 
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against p-ERK1/2 (A) and p-P38 (B), respectively.  Other treatments were followed as 
described in Materials and Methods.  The results were expressed by mean ± S.E.M. of 
relative phosphorylation (-folds).  Statistical analyses were performed using Bonferroni’s 




P<0.01, as compared to each control. (n=3) 
2.3.6 Effect of MP combined with TET on the translocation of GR 
To check the influence of TET on the GR translocation via inhibition of P-glycoprotein 
efflux function, MOLT-4 and MOLT-4/DNR T cells were treated by MP with or without TET.  
TET up to 1 μM showed little effect on the cell viability of MOLT-4 T cells (Fig. 2-6A).  
However, TET potentiated the MP suppressive effect on the proliferation of P-glycoprotein 
expressing MOLT-4/DNR T cells (Fig. 2-6B).  As shown in Fig. 2-2A (Page 37), 0.3 μM of 
TET inhibited the P-glycoprotein efflux function significantly, and thus this concentration of 
TET was used to examine its effect on GR translocation.  MP (5 ng/mL) alone induced the 
GR translocation into nuclei of MOLT-4 T cells significantly (Fig. 2-6C).  Whereas, after 
treatment by MP (5 ng/mL) alone, the GR amount in nucleus of MOLT-4/DNR T cells was 
much less than that of MOLT-4 T cells (P<0.01) (Fig. 2-6C).  The GR translocation was 
significantly recovered when the MOLT-4/DNR T cells were treated by MP combined with 
0.3 μM TET (P<0.01) (Fig. 2-6C).  Accordingly, GR expression in the cytoplasm of 
MOLT-4/DNR T cells decreased significantly by TET (Fig. 2-6D).  Increased GR 
distribution in nuclear/cytoplasm was observed after the MOLT-4/DNR T cells were treated 
by the combination of MP and TET (Fig. 2-6E)
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Fig. 2-6  Effect of 
methylprednisolone 
(MP) in the 
presence or absence 
of tetrandrine 
(TET) on the 
translocation of 
glucocorticoid 
receptor (GR) in 
MOLT-4 and 
MOLT-4/DNR T 
cells.  MOLT-4 (A) 
and P-glycoprotein 
positive 
MOLT-4/DNR (B) T 
cells were treated 
with MP with or 
without TET for 48 
h.  Cell viability 
was assessed by 
WST-8 assay. (C-E) 
Cells were treated by MP (5 ng/mL) with or without TET (300 nM) for 1 h.  Total GR in nuclear (C) and cytoplasmic (D) extracts were 
analyzed by Western blot. (E) Distribution (rate) of GR in nuclear/cytoplasmic fractions.  HDAC-1 and β-actin were used as controls for 
nuclear protein extracts and cytoplasmic extracts, respectively.  Data represented the mean ± S.E.M. of six independent experiments.  




P < 0.01 and 
***
P < 0.001).  Differences between data of MOLT-4 cells and those of MOLT-4/DNR cells or the data in cells treated by 
MP alone and those treated by MP combined with TET were analyzed using Mann-Whitney test (
##
P < 0.01). 
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2.4 DISCUSSION 
Comparing with isolated T cells, PBMCs were much closer to the human immune 
network in vivo.  Although IL-2 or anti-CD3 antibody largely stimulates T cell growth in 
PBMCs, the pharmacological parameters of immunosuppressive drugs in vitro were 
significantly correlated with the clinical efficacy of these drugs in Con A-stimulated PBMC 
culture system according to the previous reports [15, 76, 80].  Therefore, I used Con A as a 
stimulant of PBMCs with an aim to obtain clinically applicable information of TET combined 
with MP.  Thus, in this Chapter, Con A mitogen-activated PBMC culture procedure was 
chosen to examine the TET potential combined with GC.  It has been reported that 3 μM of 
TET effectively suppresses proliferation of T cells stimulated with phorbol 12-myristate 
13-acetate and anti CD28 antibody [18, 81].  Here, I showed that TET, even at the lowest 
concentration of 0.3 nM, increased the anti-proliferative effect of MP in the mitogen-activated 
PBMCs, and thus decreased the IC50 value of MP significantly (Fig. 2-2B).  Actually, TET 
itself (≤300 nM) showed no toxic effect on the ability of PBMCs to proliferate in response to 
a T-cell mitogen, Con A (Fig. 2-2A).  It would be a novel finding that the nM level of TET 
potentiates the anti-proliferative efficacy of MP on T cell mitogen-activated human PBMCs. 
P-glycoprotein, encoded by multidrug-resistance gene 1 (MDR-1), played critical role in 
GC-resistant patients. High levels of multidrug-resistance gene 1 expression had been found 
in PBMCs from patients with GC-resistant inflammatory bowel disease [82] and systemic 
lupus erythematosus [83, 84].  Rh123 accumulation in immune cells has been used as a 
standard functional indicator of multidrug-resistance gene 1 [83, 85].  The 
multidrug-resistance gene 1 modulator such as verapamil inhibited Rh123 efflux and 
increased accumulation of Rh123 in P-glycoprotein expressing cells [86].  TET (≥300 nM) 
significantly enhanced the accumulation of Rh123 in CD4
+
 T cells, CD8
+
 T cells and 
lymphocytes in PBMCs (Fig. 2-2A). TET with or without MP exhibited similar inhibitory 
effect, suggesting that MP had little influence on the action of TET (Fig. 2-2B).  GCs were 
reported to be substrates of P-glycoprotein [87], and thus increased number of P-glycoprotein 
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on the cell surface resulted in efflux of GC molecule out of the cells, decreased number of GC 
molecules in cytoplasm of T cells, and therefore impaired the GR translocation.  This 
hypothesis was subsequently confirmed by the Western blot analyses of P-glycoprotein 
negative MOLT-4 and P-glycoprotein positive MOLT-4/DNR T cells treated by MP with or 
without TET as shown in Fig 2-6.  Accordingly, the efficient suppression of P-glycoprotein 
function on the cell surface might potentiate the GC effects.  Indeed, 300 nM of TET 
significantly potentiated the inhibitory activity of extremely low concentrations (0.05 and 0.5 
ng/mL) of MP on T-cell proliferation (Fig. 2-1A).  According to a preliminary report, the 
maximum blood concentration of TET after intake of 40 mg TET could be reached to 17 μM 
in healthy male subjects [88].  Therefore, this concentration (300 nM) of TET to suppress 
P-glycoprotein function in the activated T cells could be easily obtained clinically without 
risks of side effects.  
There were considerable variabilities in the sensitivity of PBMCs from seven healthy 
subjects to the suppressive effects of MP and TET.  Both TET and MP inhibited the 
production of pro-inflammatory cytokines TNFα and IL-6 from the activated PBMCs 
significantly.  Yuan et al. reported similar inhibitory effects of TET on TNFα and IL-6 
productions by collagen-induced arthritis mice model [89].  According to these results, the 
anti-inflammation ability of TET was seemed to be almost equal to that of MP, which was a 
possible reason for the TET efficacy in treatment of rheumatic arthritis in China.  In the 
present study, I showed that the combination of TET and MP shows stronger inhibitory effect 
on the production of pro-inflammatory cytokines TNFα and IL-6 than MP alone (Fig. 2-3).  
However, the effect of the combination was not significantly superior to that of TET alone, 
indicating that there would be no interaction of these two drugs with respect of cytokine 
release suppression.  PBMCs include lymphocytes (T cells, B cells, and NK cells), 
monocytes, and dendritic cells, and T cells in PBMCs account for 45~70%.  Con A 
stimulation of PBMCs results in activation of several immune cells including T cells and 
monocytes, which relates to the increased production of IL-6 and TNFα.  Suppressive effects 
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of TET on the production of these inflammatory cytokines were beneficial for the 
anti-proliferative efficacy of GCs on the activated immune cells, especially T cells.  In 
addition to T cells, monocytes, macrophages, and dendritic cells might also be suppressed 
their function by TET.  How dose TET influence the proliferation of these immune cells, as 








 T cells were usually recognized as Treg cells, which are suggested 
to inhibit proliferation of immune cells.  Some immunosuppressive drugs such as 













 T cells were 
reported to exhibit effector/memory phenotypes without any regulatory/suppressor function 
[91, 92].  Although the function of human Treg cells is still a big controversy, I examined 






 T cells.  Either 









 cells (Fig. 2-4).  This result was also consistent with the effect of 
TET to decrease the Treg related cytokine IL-10 production (data not shown).  
GC-resistance in human T cells in vitro has been reported to happen accompanied with 
GR phosphorylation via activation of ERK1/2 pathways stimulated by microbial 
superantigens [93].  GR function could also be suppressed via phosphorylation of the 
receptor by p38 mitogen-activated protein kinase [94].  In accordance with this theory, p38 
MAPK had been shown a greater degree of activation in alveolar macrophages from asthmatic 
patients with a poor response to GC than that from patients who show a normal response [95].  
Activated JNK was reported to directly phosphorylate GR at Ser226 to inhibit binding to 
GC-response element [96].  I observed that TET at 3 μM in combination with MP inhibited 
the phosphorylation of MAPK family.  Thus, TET synergistically inhibited both ERK1/2 and 
P38 when combined with MP.  For this reason, TET is an ideal candidate to increase the 
sensitivity of activated PBMCs to GCs via suppression of MAPK-NF-κB pathways, which is 
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consistent with my results of the PBMC proliferation assay shown in Fig.2-1.  As mentioned 
above, IL-6 secretion was inhibited by TET and/or MP, which means that IL-6/ERK1/2 
cascade can be the other possible action target for TET to potentiate the MP efficacy, since 
IL-6 was reported to stimulate phosphorylation of ERK1/2 [97].  
The results obtained by use of PBMCs revealed a strong relationship between the  
inhibitory efficacy of TET on P-glycoprotein function and the antiproliferative synergic effect 
of TET combined with MP.  To confirm the influence of TET on the GR translocation via 
inhibition of P-glycoprotein efflux function, MOLT-4 and MOLT-4/DNR T cells were treated 
by MP with or without TET, as I showed in Fig. 2-6.  Compared with the parent MOLT-4 
cells, MOLT-4/DNR T cells expressed larger number of P-glycoprotein and MDR-1 gene as 
we reported before [79].  The present data suggested that highly expressed P-glycoprotein 
impaired the GR translocation into nuclei in MOLT-4/DNR T cells, as compared to the parent 
MOLT-4 T cells.  The impaired GR translocation in MOLT-4/DNR T cells was recovered 
by TET.  This theory was consistent with the data of cell proliferation as shown in Fig. 2-6A 
and B.  TET showed little influence on the MP pharmacodynamics on MOLT-4 T cell 
proliferation, whereas TET dose-dependently enhanced the inhibitory effect of MP on 
MOLT-4/DNR T cells expressing high amount of P-glycoprotein on the cell membrane.   
2.5 CONCLUSION 
TET decreased the IC50 value of MP, while it showed little toxic effect on the Con 
A-activated PBMCs.  Both TET and MP inhibited the secretion of pro-inflammatory 
cytokines TNFα and IL-6 and the combination showed stronger ability.  TET and/or MP did 






 T cells.  However, TET with or without 




 T cells and lymphocytes.  
TET tended to suppress the phosphorylation of MAPK and this effect was potentiated by MP.  
Meanwhile, TET enhanced the inhibitory effect of MP on P-glycoprotein expressing 
MOLT-4/DNR T cells with little effect on the parent MOLT-4 T cells.  Inhibition of 
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P-glycoprotein function by TET is suggested to be related to increase in the GR translocation 
into nucleus.  These TET effects seem to be beneficial for improving immunosuppressive 
efficacy of GCs.  GC combined with TET could be a new therapeutic approach to resolve 
GC-resistance possibly via inhibiting P-glycoprotein function and blocking MAPK signaling 










Immunosuppressive efficacy of tetrandrine combined with 
methylprednisolone against mitogen-activated peripheral blood 
mononuclear cells of hemodialysis patients 
3.1 INTRODUCTION 
According to our previous research, a significantly large population of dialysis patients 
(26.2%), when compared with the healthy subjects (4.1%), showed a marked decrease in 
lymphocyte response to the suppressive effects of prednisolone [80].  It is worthy to develop 
new therapeutic approaches, which can decrease the doses, and therefore adverse effects, of 
GCs and other immunosuppressive drugs for renal transplant recipients. 
As shown in Chapter 2, TET potentiated immunosuppressive effects of MP through 
P-glycoprotein/MAPK/GR signaling pathway in PBMCs of healthy subjects.  Considering 
the characteristics of T lymphocytes of renal transplant recipients, it is necessary to confirm 
the synergic effect of TET and MP in PBMCs of hemodialysis patients. 
Thus, in this Chapter, the synergic immunosuppressive effects of TET with MP were 
examined in T cell mitogen-activated PBMCs of hemodialysis patients, and the drug efficacy 
in vitro was related to the clinical parameters of the patients. 
3.2 MATERIALS AND METHODS 
3.2.1 Drugs and reagents 
RPMI1640, FBS, Con A, TET, MP, WST-8 assay kits, and BD Cytometric Bead Array 
(CBA) Human Th1/Th2/Th17 Cytokine Kit were obtained as described in Chapter 2.  The 
stock solutions of TET and MP were prepared as mentioned in Chapter 2, and stored at 4℃ 
until use.  All other reagents were of the highest quality available from commercial vendors. 
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3.2.2 Subjects 
The study was conducted in accordance with the Declaration of Helsinki and was 
approved by the institutional ethics committee for studies in human in both Keiyu Hospital 
and Tokyo University of Pharmacy and Life Sciences.  All hemodialysis patients (three 
females and ten males with the age of 67.69 ± 15.06) and healthy subjects (six females and 
five males with the age of 31.64±13.37) gave their written informed consent for blood 
donation.  Healthy subjects had neither a history of immunological disorders nor a history of 
taking immunosuppressive drugs including steroids.  Basic characteristics of the patients 
including gender, age, duration of hemodialysis, white blood cell counts, C-reactive protein 
concentration, and serum creatinine concentration were shown in Table 1. 
3.2.3 Preparation of PBMCs 
Twenty milliliters of heparinized venous blood were taken from healthy subjects and 
patients.  This 20 mL sample size was the smallest possible to examine the 
immunosuppressive efficacy of TET in the presence or absence of MP.  The heparinized 
blood was loaded on 3 mL of Ficoll-Hypaque (Nakarai Co., Japan), and centrifuged at 1300 
×g for 20 min. PBMCs were separated and suspended with RPMI 1640 medium containing 10% 
FBS, 100,000 IU/L penicillin G sodium salt and 100 mg/L streptomycin sulfate to a final 
density of 1 × 10
6
 cells/mL as I described previously.
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Table 1.  Characteristics and laboratory data of the hemodialysis patients 
Case Gender Age 
Duration of 
hemodialysis (years) 




1 M 86 0 5300 0.62 3.86 3.85 
2 M 71 0 6200 0.01 9.18 1.77 
3 F 83 0.75 5500 0.51 4.48 2.05 
4 M 62 1 6800 0.42 15.74 1.60 
5 M 86 2 7600 1.05 6.42 1.95 
6 M 77 1 5300 0.05 5.69 1.20 
7 M 71 7 6800 0.44 11.91 1.54 
8 F 79 7 4300 0.05 8.53 4.24 
9 F 66 0 8600 0.24 8.13 1.49 
10 M 49 0 9400 0.10 7.10 1.96 
11 M 45 0 8700 0.20 10.24 1.71 
12 M 42 0 6000 0.38 15.18 1.27 
13 M 63 0 6500 0.62 6.47 1.63 
Mean±SD 67.69±15.06 1.44±2.54 6692.21±1517.39 0.36±0.30 8.69±3.74 2.02±0.94 
Median 71 0 6500 0.38 8.13 1.71 
Minimum 42 0 4300 0.01 3.86 1.20 
Maximum 86 7 9400 1.05 15.74 4.24 
Abbreviated symbols: WBC, white blood cells; CRP, C-reactive protein; CRE, creatinine. 
†
PBMC proliferation ratio between cells cultured 
in the presence and absence of concanavalin A (see Materials and Methods). 
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3.2.4 Evaluation of drug pharmacodynamics in vitro 
194 μL of PBMCs suspension were loaded into wells of a 96-well plate.  Con A was 
added to each well to a final concentration of 5.0 μg/mL.  Subsequently, 4 μL of an ethanol 
solution containing TET were added to give a serial concentrations of 0.3 nM to 30 μM.  To 
evaluate the synergistic effect of TET combined with MP, 2 μL of an ethanol solution 
containing MP were added to give final concentrations of 0.05, 0.5, 5, 50 and 500 ng/mL, 
respectively.  Six microliters of ethanol were added to the control wells.  The plate was 
incubated for 96 h in 5% CO2 at 37℃.  After the culture, 10 μL of WST-8 assay reagent 
solution were added to each well, and the plate was incubated for another 3 h.  The optical 
density value was measured at 450 nm absorbance (ref. 650 nm).  PBMCs proliferation was 
calculated by (Test-Blank)/(Control-Blank)×100%. 
3.2.5 Quantification of human cytokines 
PBMCs were incubated for 96 h in the presence of Con A, TET and MP together or 
respectively as described above, and the culture supernatant was stored at −80℃ until 
measurement of cytokine concentrations.  The concentrations of interferon (IFN)-γ, TNF-α, 
IL-2, -4, -6, -10 and -17 in the culture supernatant were measured with beads-array procedures 
using the Human Th1/Th2/Th17 Cytokine Kit, followed by flow cytometry, according to the 
instructions of BD Biosciences (San Jose, CA).  The data were analyzed using BD™ 
Cytometric Bead Array (CBA) FCAP Array Software. 
3.2.6 Statistical analysis 
The correlation coefficients between the IC50 values of the drugs and the basic 
characteristics of the hemodialysis patients were analyzed using Pearson’s test.  Differences 
of median values for the drug IC50 values or stimulation indices between any two subject 
groups were analyzed by Mann-Whitney’s U-tests.  Differences in the amounts of cytokines 
produced in the culture medium between control and the drug-treated cell fractions were 
analyzed with Wilcoxon matched-pairs signed rank test.  The synergic effects of TET to 
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potentiate MP immunosuppressive pharmacodynamics were analyzed by Kruskal-Wallis test.  
These analyses were performed with GraphPad PRISM 5.0.  In each case, two-sided P 
values <0.05 were considered to be significant. 
3.3 RESULTS 
3.3.1 Effects of MP on mitogen-activated proliferation of PBMCs of hemodialysis 
patients and healthy subjects 
The effects of MP on Con A-activated proliferation of PBMCs of hemodialysis patients 
and healthy subjects were examined.  MP dose-dependently suppressed the PBMC 
proliferation as shown in Fig. 3-1A.  PBMCs derived from two out of 13 hemodialysis 
patients showed low-responses to MP, and the IC50 values of MP on the proliferation of 
PBMCs from these patients gave more than 400 ng/mL (Case 5 and Case 9, Table 2).  
Meanwhile, none of the low-responders were observed in 11 healthy subjects.  Typical 
dose-response curves of PBMCs obtained from hemodialysis patients against the suppressive 
effects of MP in the low-responder (Case 5), the high-responder (Case 1) and the 
normal-responder (Case 7) were presented in Fig. 3-1B.  Although the stimulation indices 
(the ratio of PBMC proliferation stimulated and unstimulated by Con A) on PBMCs of the 
patients were significantly lower than those of the healthy subjects (Fig. 3-2B, P=0.02), there 
was no significant difference between the MP effects on patient PBMCs and those on healthy 
PBMCs (Fig. 3-2A, P=0.45).  The median (range) of MP IC50 values against the 
proliferation of patient PBMCs was 7.04 (2.30~500.00) ng/mL, while the median (range) 
value against the healthy PBMCs was 4.44 (3.19~5.08) ng/mL.  Obviously, the individual 
difference of MP IC50 values against the proliferation of patient PBMCs was much larger than 












Fig. 3-1  Effects of methylprednisolone on proliferation of PBMCs of hemodialysis 
patients activated with concanavalin A.  Cell proliferation was determined by WST-8 
assay.  (A) Inhibition of PBMC proliferation by MP. The data were expressed as mean ± 




P<0.001  (B) Typical 
dose-response curves of MP against concanavalin A-stimulated proliferation of PBMCs 









Fig. 3-2  Comparison of methylprednisolone (MP) IC50 values (A) and stimulation 
indices (B) after the stimulation by concanavalin A between PBMCs of the hemodialysis 
patients and healthy subjects. The data were analyzed by Mann-Whitney test. 
3.3.2 Effects of TET on mitogen-activated PBMC proliferation of hemodialysis patients 
Effects of TET against the Con A-stimulated proliferation of PBMCs of hemodialysis 
patients were presented in Fig. 3-3.  TET at concentrations ≤300 nM showed little toxicity, 
but TET at concentrations ≥3 μM exhibited strong inhibitory effects on the proliferation of 
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PBMCs of hemodialysis patients.  The median (range) of TET IC50 values against the 






3.3.3 Effects of combination of MP and TET on mitogen-activated proliferation of 
PBMCs obtained from hemodialysis patients 
In order to examine the influences of TET on the MP immunosuppressive effect, lower 
concentrations of TET (≤300 nM) were used to examine the additive efficacy of this 
compound.  The median (range) of MP IC50 values was 7.04 (2.30~500.00) ng/mL as 
described above, whereas the median (range) IC50 values of MP combined with 0.3, 3, 30 and 
300 nM TET were 0.92 (0.49~8.39), 2.10 (0.45~20.00), 0.35 (0.092~1.05), and 0.14 
(0.05~6.78) ng/mL, respectively (Table 2).  30 and 300 nM TET significantly decreased the 
IC50 values of MP (P<0.05, Fig. 3-4).  The more important finding is that nM of TET 
decreased the MP IC50 values on the Con A activated proliferation of PBMCs of the 





Fig. 3-3  Effects of tetrandrine (TET) on 
proliferation of PBMCs of hemodialysis 
patients activated with concanavalin A.  
Cell proliferation was determined by WST-8 
assay.  The data were expressed as mean ± 






Fig. 3-4  Synergic effects of tetrandrine 
(TET) to potentiate the suppressive effect of 
methylprednisolone (MP) on the proliferation 
of concanavalin A-stimulated PBMCs 
obtained from hemodialysis patients.  The 




Table 2.  IC50 values of drugs on concanavalin A-stimulated proliferation of PBMCs of hemodialysis patients  
Case 






IC50 values of MP 
in combination 
MP+TET 0.3 nM 
(ng/mL) 
IC50 values of MP 
in combination 
MP+TET 3 nM 
(ng/mL) 
IC50 values of MP 
in combination 
MP+TET 30 nM 
(ng/mL) 
IC50 values of MP 
in combination 
MP+TET 300 nM 
(ng/mL) 
1 0.08 0.81 - - - - 
2 52.53 2.17 24.33 20.00 29.88 - 
3 2.12 0.02 0.59 0.70 0.05 0.05 
4 87.10 1.26 3.08 33.67 0.092 12.58 
5 500.00 0.74 90.42 28.37 13.56 15.49 
6 7.04 2.89 1.13 2.48 0.40 0.05 
7 2.26 1.62 1.90 0.45 0.35 0.05 
8 31.75 30.00 - 0.21 0.34 0.05 
9 431.20 9.40 - - - - 
10 3.87 2.26 0.70 2.10 0.70 0.25 
11 2.65 1.46 0.14 0.14 0.05 0.97 
12 2.34 6.69 0.17 1.15 0.34 - 
13 13.64 1.31 0.64 4.11 1.05 0.14 
Mean±SD 87.43±170.34 4.66±8.05 12.31±28.42 8.49±12.55 4.26±9.38 3.29±6.14 
Median 7.04 1.61 0.92 2.10 0.35 0.14 
Minimum 0.08 0.02 0.14 0.14 0.05 0.05 
Maximum 500.00 30.00 90.42 33.67 29.88 15.49 
Abbreviated symbols: PBMCs, peripheral blood mononuclear cells; MP, methylprednisolone; TET, tetrandrine; SD, standard deviation 
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3.3.4 Relationship between immunosuppressive potencies of the drug and clinical 
parameters of hemodialysis patients 
In order to examine relationship between the drug effects on PBMCs and the patient 
characteristics or laboratory diagnostic data, the IC50 values of TET and MP were analyzed for 
their relation with each of 6 factors: proliferation stimulation indices by mitogen, ages, 
durations of dialysis, white blood cell (WBC) counts, serum creatinine (CRE) concentrations, 
and C-reactive protein (CRP) concentrations (see Table 1).  There was significant 
correlation between IC50 values of TET and the stimulation indices (P=0.04, r=0.58) or the 
durations of hemodialysis (P=0.04, r=0.57).  The IC50 values of MP in combination with 
0.3nM TET and the CRP concentrations also showed a significant correlation (P=0.04, r=0.64) 
(see Table 3).  Finally, there was no significant correlation between the IC50 values of TET 
and those of MP (P=0.94, r=0.02).  
3.3.5 Effects of TET in the presence or absence of MP on IL-6 production from 
mitogen-activated PBMCs of hemodialysis patients 
The effects of MP in combination with TET on the production of Th1/Th2/Th17 
cytokines (IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ and IL-17) were examined.  The 
concentrations of cytokines in the culture supernatant of Con A-activated PBMCs were 
measured.  3 nM TET significantly potentiated the suppressive effect of 0.05 ng/mL MP, as 
compared to the effect of MP alone, on the production of pro-inflammatory cytokine IL-6 
(P<0.05, Fig. 3-5).  Similar synergic inhibitory effects was observed in the combination of 
300 nM TET and 0.5 ng/mL MP.  In contrast, no such synergic effect of TET with MP on the 
production of the other cytokines was observed (data not shown). 
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Table 3.  Relationship between IC50 values of drugs on PBMC proliferation and patient-related factors  











WBC CRE CRP 
TET 





 0.21 0.79 0.17 
MP 
r 0.27 -0.14 -0.06 0.38 -0.10 0.44 
P 0.37 0.65 0.85 0.20 0.74 0.13 
MP+TET 0.3 nM 
r 0.52 0.35 0.10 0.14 -0.24 0.64 
P 0.12 0.33 0.79 0.70 0.51 0.04* 
MP+TET 3 nM 
r 0.25 -0.15 -0.18 0.13 0.26 0.39 
P 0.46 0.67 0.59 0.71 0.44 0.23 
MP+TET 30 nM 
r 0.28 -0.05 -0.19 0.00 -0.11 -0.02 
P 0.41 0.89 0.58 1.00 0.74 0.95 
MP+TET 300 nM 
r 0.23 -0.14 -0.12 0.19 0.34 0.66 
P 0.55 0.72 0.75 0.62 0.37 0.05 
Abbreviated symbols: MP, methylprednisolone; TET, tetrandrine; WBC, white blood cells; CRP, C-reactive protein; CRE, creatinine; 
Stimulation index represents the peripheral blood mononuclear cell proliferation ratio between cells cultured in the presence and absence of 















The present study was conducted to examine immunosuppressive efficacy of TET in 
combination with MP on the T cell mitogen-stimulated proliferation of PBMCs obtained from 
hemodialysis patients, which would be candidates for renal transplant recipients.  The data 
showed that TET can potentiate the MP immunosuppressive pharmacodynamics to inhibit T 
cell mitogen-stimulated proliferation of PBMCs obtained from hemodialysis patients, as well 
as that of PMBCs obtained from healthy subjects as I described in Chapter 2.  
There were gender and age mismatches between the cases and the healthy subjects in this 
study.  However, there were no significant correlations between the IC50 values of MP or 
TET and the ages of patients or healthy subjects (data not shown).  In addition, the IC50 
values of MP and TET did not significantly differ between male and female patients or 
healthy subjects.  From these observations, I suggested that these indices would not 
influence basically the present findings. 
There was no significant difference in the PBMC sensitivity to the suppressive efficacy 
of MP between healthy subjects and hemodialysis patients (Fig. 3-2A), which was consistent 
with the data we reported in 1994 [80].  However, the median (range) of the IC50 values 
Fig. 3-5  IL-6 concentrations in the 
supernatant of concanavalin A-stimulated 
PBMCs of hemodialysis patients cultured 
in the presence of tetrandrine (TET) 
and/or methylprednisolone (MP).  The 
data were expressed as mean ± SEM and 
analyzed by Wilcoxon matched-pairs signed 





showed that there was a large individual deviation in the pharmacological responses of 
PBMCs to the suppressive efficacy of MP in hemodialysis patients, when comparing with the 
PBMCs of healthy subjects.  Meanwhile, typical low, normal, and high responders to MP in 
13 hemodialysis patients were observed (Fig. 3-1B).  When these patients receive renal 
transplantation and MP immunosuppressive therapy, it would be essential to recommend 
therapeutic MP doses individually to minimize the adverse events.   
In this Chapter, I also revealed that there was a significant difference between the 
stimulation indices in healthy PBMCs and those in PBMCs of hemodialysis patients (P=0.02, 
Fig. 3-2B).  The mean (SD) ages of patients and healthy subjects were 67.69 (15.06) and 
31.64 (13.37), respectively, and a significant difference (P=0.0002) was observed between 
these two groups.  The difference of ages led to different stimulation indies of PBMCs [98].  
Many reports showed impaired immune function in hemodialysis patients [99, 100], which 
might be another reason for the decrease in the stimulation index in PBMCs of the 
hemodialysis patients. 
In Chapter 2, nM grade of TET was found to potentiate the GC pharmacodynamics via 
inhibiting P-glycoprotein and MAPK in mitogen-activated PBMCs of healthy subjects in vitro.  
Considering the differences of immune system between healthy subjects and patients, I 
continued to examine the immunosuppressive effect of TET by using the PBMCs isolated 
from the blood of hemodialysis patients.  The PBMC culture system appears to be more 
close to the immune system of hemodialysis patients as compared to the system consisted of 
isolated T cells.  The median (range) of TET IC50 values in the 13 patients was 1.61 
(1.04~4.79) μM.  According to a preliminary report of Dong, the maximum blood 
concentration of TET after intake of 40 mg TET could be reached to 17 μM in healthy male 
subjects [88].  Therefore, the IC50 value of TET to suppress T cell proliferation could be 
easily obtained clinically without risks of side effects.  Only the Case 8 examined in this 
study showed limited sensitivity towards the TET effect.  In contrast, the Case 5 was a 
typical low-responder to MP (IC50; 500 ng/mL) with high sensitivity towards TET (IC50; 0.74 
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μM) (Table 2).  Similar result was also observed on Case 9 (Table 2).  These observations 
reminded us that the pharmacological target was different between MP and TET. 
The more important finding was that the lower concentrations of TET (0.3-300 nM) 
decreased the IC50 value of MP, suggesting that TET can potentiate the MP 
immunosuppressive pharmacodynamics (Fig. 3-4).  Thus, TET appears to be able to reduce 
the therapeutic GC doses, which results in attenuation of severe GC side effects such as 
osteoporosis, gastrointestinal ulcer, infectious diseases, etc.  Whereas, the lower 
concentrations of TET (0.3-300 nM) alone showed little effect on the PBMC proliferation 
(Fig. 3-3).   
Then, I examined correlations between the IC50 values of the drugs and the basic 
characteristics including laboratory data of the hemodialysis patients (Table 3).  The IC50 
values of MP significantly correlated with CRP values (P=0.04, r=0.64), which reminded us 
to pay more attention to infectious diseases or other long-term inflammatory diseases in these 
patients.  There was no correlation between IC50 values of TET and MP (r=0.02), suggesting 
that the immunosuppressive mechanisms of TET and MP were different, and thus the 
combination of TET and MP would be a possible strategy for renal transplant recipients to 
potentiate the MP efficacy.  
IL-6 was reported to stimulate phosphorylation of ERK1/2 [97, 101]. The 
phosphorylation via MAPK such as ERK1/2 modulates trafficking of GR and impairs its 
transcriptional activity, which leads to GC resistance [14, 102, 103].  In Chapter 2, I also 
showed that TET increases the MP sensitivity by inhibiting the secretion of IL-6 and MAPK 
in mitogen-activated PBMCs of healthy subjects.  For PBMCs of hemodialysis patients, I 
observed similar effect of TET on the production of IL-6.  As mentioned above, among the 
Th1/Th2/Th17 cytokines (IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ and IL-17), only the 
secretion of the pro-inflammatory cytokine IL-6 was inhibited synergistically by the 
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combination of TET and MP.  These observations suggest that IL-6/ERK1/2 cascade is a 
possible action target of TET to potentiate the MP pharmacodynamics. 
3.5 CONCLUSION 
TET potentiates the MP immunosuppressive pharmacodynamics to inhibit T cell 
mitogen-stimulated proliferation of PBMCs obtained from hemodialysis patients in vitro.  
According to these observations, it seems to be possible to combine MP and TET for 
treatment of patients to reduce the MP therapeutic dose and thus decline its side effects.   
The IC50 values of MP in combination with TET significantly correlated with CRP 
concentrations of hemodialysis patients. Whereas, the pharmacological efficacy of TET 
and/or MP did not correlate with patient ages, durations of hemodialysis, white blood cell 
counts, or serum creatinine concentrations. 
Combined with my findings mentioned in Chapters 2 and 3, the combination of TET and 
MP is extremely suitable for the GC resistant patients who are planning to receive renal 











Plant-derived alkaloid sinomenine potentiates steroid pharmacodynamics 
in mitogen-activated human peripheral blood mononuclear cells by 
regulating the translocation of glucocorticoid receptor 
4.1 INTRODUCTION 
As shown in Chapters 2 and 3, TET isolated from Stephania tetrandra S. Moore (中国産
防已) potentiates MP immunosuppressive effect through P-glycoprotein/MAPK/GR signaling 
pathway.  Chinese Pharmacopeia (2015 edition) lists the Radix Stephaniae Tetrandrae as 
Boui, whereas Caulis Sinomenii is collected as the herb of Boui in Japanese Pharmacopeia 
(17
th
 edition).  Sinomenine (SN, Fig. 4-1) is the main active alkaloid of herbal plant 
Sinomenium acutum (Thunb.) (日本産防已).  Lots of studies also indicated that SN shows 
anti-rheumatoid arthritis effects by inhibiting lymphocyte proliferation [22, 23].  Moreover, 
SN was reported to downregulate P-glycoprotein expression and inhibit the efflux function of 





Fig. 4-1  Chemical structure of sinomenine (SN) 
Thus, in this Chapter, I also evaluated the potential additive effects of SN on the GC 
pharmacodynamics in vitro to suppress the proliferation of human T lymphocytes with a focus 
on P-glycoprotein function regulation and GR translocation.     
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4.2 MATERIALS AND METHODS 
4.2.1 Drugs and reagents 
RPMI 1640, FBS, and Con A were purchased from Seikagaku Kogyo Co., Tokyo, Japan.  
SN originated from Sinomenium acutum with a purity of more than 98% and verapamil were 
purchased from Sigma Aldrich (St. Louis. Mo., USA).  SN was dissolved in ethanol at a 
concentration of 15 mM, filtered through a 0.2 μm membrane filter (Advantec Co., Japan), 
and then stored at 4℃ until use.  The working concentrations were prepared by dilution with 
ethanol.  MP was provided from Sigma Aldrich (St. Louis. Mo., USA), dissolved in ethanol, 
and stored at 4℃ until use.   The cell proliferation WST-8 assay kits were obtained from 
Dojindo Molecular Technologies, Inc., Japan.  FITC mouse anti-human CD4, and APC 
Mouse Anti-Human CD8 were obtained from BD Biosciences, San Jose, CA, USA.  GR 
antibody (G-5) was provided by Santa Cruz Biotechnology, INC (dilution 1:1000, # 
sc-393232).  β-actin was purchased from Proteintech Group (dilution 1:5000, # 66009-1-Ig).  
Anti-TATA binding protein (TBP) antibody was obtained from Abcam (dilution 1:1000, # 
ab818).  All other reagents were of the highest quality available from commercial vendors. 
4.2.2 Subjects 
The present study was carried out in accordance with The Code of Ethics of the World 
Medical Association (Declaration of Helsinki).  The study was approved by the Ethical 
Committee of Tokyo University of Pharmacy and Life Sciences and written informed consent 
was obtained from all healthy subjects included in the study.  The study included 7 healthy 
subjects (4 males and 3 females with a mean age of 26.8 years).  These subjects had neither a 
history of immunological disorders nor a history of taking immunosuppressive drugs 
including steroids. 
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4.2.3 Isolation and culture of PBMCs, and evaluation of drug effects in vitro 
The experiments were basically carried out according to the procedures as I mentioned in 
Chapters 2 and 3.  To examine the effects of SN combined with MP on the proliferation of 
Con A-activated PBMCs, 2 μL of MP solution giving a final concentration of 0.05, 0.5, 5, or 
50 ng/mL and 4 μL of an ethanol solution containing SN to give a final concentration of 0.03, 
0.3, 3, 30, or 300 μM was added to the culture well, respectively.  Six microliters of ethanol 
were added to the control wells.  The plate was incubated for 96 h in 5% CO2 at 37℃, and 
the PBMC proliferation was assessed by WST-8 assay procedures as described in Chapters 2 
and 3.  
4.2.4 Functional assays for P-glycoprotein in PBMCs 
Basically, the assay was carried out according to the method described in Chapter 2.  In 
brief, Rh123-treated PBMCs were re-suspended in a Rh123-free complete media with or 
without 0.03, 0.3, 3, 30, or 300 μM SN, combining with or without 0.5 ng/mL MP, 0.5 ng/mL 
MP and 5 μM verapamil at 37℃ for 180 min.  After the efflux period, cells were washed 
twice with ice-cold 10%FBS in PBS and were then stained with FITC mouse anti-human CD4 
and APC Mouse Anti-Human CD8.  After staining, the cells were washed twice and then 
re-suspended in PBS and kept on ice in the dark until analysis by FACSCanto ™ II as I 
described before (BD Biosciences, San Jose, CA) 
4.2.5 Jurkat cell culture 
Human leukemic Jurkat T-cells were purchased from ATCC and cultured in RPMI 1640 
medium containing 10% FBS, 100,000 IU/L penicillin G sodium salt and 100 mg/L 
streptomycin sulfate, at 37℃ in a humidified atmosphere of 5% CO2.  In order to prepare 
cells for Western blot analysis and immunofluorescence, cells were cultured with different 
concentrations of SN (0.03, 0.1, 0.3, 1 and 3 μM) and/or MP (5 ng/mL). 
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4.2.6 Western blot analysis 
PBMCs and Jurkat cells were pre-treated with SN for 24 h and harvested in 2 h after MP 
treatment.  Cytoplasmic and nuclear proteins were extracted using the Thermo Scientific 
NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce Biotechnology, Rockford, IL, 
USA) according to manufacturer’s instruction.  Protein concentration was quantified by 
Pierce BCA Protein Assay Kit (Thermo Scientific).  Cytoplasmic and nuclear extractions 
were subsequently separated by SDS-polyacrylamide gel electrophoresis and then 
electrotransferred to hydrophobic polyvinylidene fluoride membrane (Immobilon-P; Merck 
Millipore, Darmstadt, Germany).  Membranes were blocked with 5% skimmed milk for 1 h 
and washed with Tris-buffered saline/0.1% Tween-20 (TBST) subsequently.  Then, the 
membranes were incubated with primary antibodies against individual proteins overnight at 
4℃.  After triple washing with TBST, the membranes were continued to incubate with 
secondary antibody (Anti-mouse IgG, HRP-linked, #7076, Cell Signaling Technology, Inc.) 
at a dilution of 1:1000 at room temperature for 1 h.  After triple washing with TBST, the 
signals were detected with an ECL or ECL Prime Western Blotting detection kit (GE 
Healthcare) in a luminescent image analyzer (Fujifilm; LAS-3000; Fujifilm, Tokyo, Japan).  
The images were quantitatively analyzed by ImageJ software (version 1.52e, National 
Institutes of Health, USA; http://imagej.nih.gov/ij). 
4.2.7 Immunofluorescence 
In order to confirm the effect of SN on GR subcellular compartmentalization, Jurkat cells 
were subjected to immunofluorescence after treatment with SN and/or MP.  Briefly, Jurkat 
cells were treated with SN for 24 h and then cultured with MP for another 2 h.  Cells were 
harvested and fixed with 4% paraformaldehyde. After washing with PBS, cells were blocked 
in PBS contained with 3% BSA and 0.5% triton-X at room temperature for 1 h and incubated 
with primary GR antibody (1:100; G-5, sc-393232, Santa Cruz, CA, USA) at 4℃ overnight.  
After washing with PBS, cells were continued to incubate with second goat anti-mouse 
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antibody (1:500; Alexa Fluor 488 goat anti-mouse IgG/IgM, # A-10680, Invitrogen) at room 
temperature for 1 h, followed by 10 min staining of nucleus with Hoechst 33342 (#17535, 
AAT Bioquest, Inc, CA, USA).  Images were captured with a fluorescence microscope 
(Biozero BZ-8000 Series, Keyence, Japan).  Signals were quantified using ImageJ program 
as mentioned above.  A same size area was selected and the signal was measured in each 
nucleus, giving the intensity in arbitrary unit. 
4.2.8 Statistical analysis 
Differences in the percentages of PBMC-proliferation, IC50 values of drugs, Rh123 
accumulated amounts, and protein expression levels between controls and the cell fractions 
treated with serial concentrations of drugs were analyzed with Bonferroni tests.  Expression 
and subcellular localization of GR in Jurkat cells after treatment with MP and/or SN were also 
analyzed with Bonferroni tests.  Differences in subcellular localization of GR in Jurkat cells 
or PBMCs between control cells and the cells treated with serial concentrations of MP and/or 
SN were analyzed by Dunnett's Multiple Comparison Test.  These analyses were performed 
with GraphPad PRISM 5.0 (GraphPad Software Inc., San Diego, CA).  In each case, 
two-sided P values <0.05 were considered to be significant. 
4.3 RESULTS 
4.3.1 Effects of SN in the presence or absence of MP on mitogen-activated proliferation 
of PBMCs 
The effects of SN on cell proliferation of PBMCs activated with a T-cell mitogen, Con A 
were examined in vitro (Fig. 4-2A).  SN at concentrations of 0.03~3 μM showed a little 
inhibitory effects, but SN at concentrations ≥ 30 μM exhibited strong suppressive effects on 
the activated proliferation of PBMCs (P<0.001).  The median (range) of SN IC50 values 
against the proliferation of PBMCs was 38.4 (2.51~187.00) μM. 
Then, I examined the additive efficacy of SN with MP to suppress the proliferation of 
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mitogen-activated PBMCs of healthy subjects.  The median (range) of MP IC50 values was 
3.18 (0.45~6.81) ng/mL, whereas those of MP combined with 0.03, 0.3, 3 and 30 μM of SN 
decreased dose-dependently to 1.85 (0.05~5.15), 0.83 (0.10~3.90), 0.56 (0.09~1.62) and 0.59 
(0.05~1.30) ng/mL, respectively (Fig. 4-2B).  The additive effect of 30 μM SN compared 








Fig. 4-2  Effects of methylprednisolone (MP) in the presence or absence of sinomenine 
(SN) on proliferation of PBMCs activated with concanavalin A.  Cell proliferation was 
determined by WST-8 assay.  The IC50 values were calculated by GraphPad Prism 5.  (A) 
Effects of SN on the proliferation of PBMCs.  (B) IC50 values of MP in the presence or 
absence of SN on the PBMC proliferation.  The data were expressed as means ± S.E.M. 






4.3.2 Effects of SN in the presence or absence of MP on P-glycoprotein function of 
PBMCs 
Next, I investigated whether SN suppressed the function of P-glycoprotein in PBMCs to 
enhance the GC immunosuppressive effect (Fig. 4-3).  SN at 0.03 to 30 μM did not show 




 T cells or lymphocytes.  300 μM 
of SN tended to suppress the P-glycoprotein function of these immune cells, but the effect 
was not significant (Fig. 4-3A).  Similar tendency was observed in the combination of MP 
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and SN (Fig. 4-3B).  In contrast, verapamil at 5 μM significantly inhibited the efflux 











Fig. 4-3  Rh123 accumulation in PBMCs in the presence of sinomenine (SN).  PBMCs 
were incubated with 2 μM Rh123 to uptake the fluorescent dye for 10 min.  Subsequently, 
the cells were washed and cultured with or without drugs to efflux intracellular dye for 180 
min.  (A) Effects of SN, as compared with verapamil (VP), the prototype P-glycoprotein 
blocker, on P-glycoprotein function of PBMCs.  PBMCs were incubated with 0.03~300 μM 
of SN for the efflux period, and the Rh123 accumulation was measured by flow cytometry.  
(B) P-glycoprotein inhibitory effect of SN in the presence of methylprednisolone (MP).  
Rh123 mean fluorescence intensities were detected by flow cytometry analysis, and Rh123 
accumulated (%) was calculated by the formula: Dye accumulated/Dye uptaken × 100 (%).  
The results were expressed as means ± S.E.M.  Statistical analyses were performed using 
Bonferroni’s multiple comparison tests. 
*
P<0.05 as compared to the group without drugs. 
#
P<0.05 as compared to the group treated with MP alone. (n=3) 
4.3.3 Effects of SN in the presence of MP on GR expression level and GR subcellular 
localization of Jurkat cells 
To further investigate the underlying mechanism of the additional effect of SN on GC, 
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the GR expression levels and GR subcellular localization were evaluated.  Nuclear and 
cytoplasmic extractions were subjected to Western blot analysis.  As shown in Fig. 4-4A, the 
levels of GR expression in nucleus was upregulated by 5 ng/mL of MP in Jurkat cells, and this 
GR upregulation effect of MP was significantly potentiated by 0.3 (P<0.05), 1 (P<0.001) and 
3 μM (P<0.001) of SN in a dose-dependent manner.  Meanwhile, SN itself also seemed to 
increase the GR expression in the nucleus of Jurkat cells, although these effects were 
negatively correlated to the dose of SN (dose range 0.3~3 μM) and the data were not 
significant.  However, the levels of GR expression in cytoplasm were not dramatically 
changed by MP and/or SN (Fig. 4-4B). 
As shown in Fig. 4-4C, after 2 h treatment by MP, the ratio of GR distribution in nucleus 
and cytoplasm was changed, and thus GR was suggested to be translocated into nucleus.  
However, the influences of SN in combination with MP on GR distribution were obvious, 
comparing with the MP alone.  Therefore, the combination of MP and SN changed the ratio 






Fig. 4-4  Expression and subcellular localization of GR in Jurkat cells after treatment 
with methylprednisolone (MP) and/or sinomenine (SN).  Western blot analysis and 
densitometric quantification of total GR in nuclear (A) and cytoplasmic (B) extracts of Jurkat 
cells.  Distribution of GR in nuclear/cytoplasmic fractions (C).  Cells were pre-treated with 
SN for 24 h, and harvested at 2 h after MP treatment.  Nuclear protein extracts were 
normalized to TATA-binding protein (TBP) and cytoplasmic extracts to β-actin.  Data 
represented the mean ± S.E.M. of seven independent experiments.  Statistical analyses were 




P < 0.01 and 
***
P < 0.001, 
as compared to the control group, respectively. 
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4.3.4 Effects of SN alone on GR expression level and GR subcellular localization of 
Jurkat cells 
As mentioned above, SN alone at 0.3~3 μM showed a tendency to upregulate GR 
expression levels in the nucleus of Jurkat cells, though the effects were negatively 
dose-dependent.  To confirm the effect of SN without GC on GR translocation, a wide 
concentration range of SN (0.03~3 μM) was chosen to investigate (Fig. 4-5).  SN increased 
the GR expression in the nucleus dose-dependently.  Among the five experimental doses of 
SN, 0.3 μM of SN showed the strongest effect to upregulate the nuclear GR expression level 
(P<0.01, Fig. 4-5A).  All the experimental doses of SN had little effects on the cytoplasmic 
GR expression, although larger doses (≥ 1 μM) showed tendency to increase GR expression in 
cytoplasm (Fig. 4-5B).  Thus, the ratio of GR distribution in nucleus and cytoplasm was 







Fig. 4-5  Expression and subcellular localization of GR in Jurkat cells after treatment 
with sinomenine (SN) alone.  Western blot analysis and densitometric quantification of 
total GR in nuclear (A) and cytoplasmic (B) extracts of Jurkat cells.  Distribution of GR in 
nuclear/cytoplasmic fractions (C).  Cells were pre-treated with SN for 24 h or MP as positive 
control for 2 h. Nuclear protein extracts were normalized to TATA-binding protein (TBP) and 
cytoplasmic extracts to β-actin.  Data represented the mean ± S.E.M. of seven independent 
experiments.  Statistical analyses were performed using Bonferroni's multiple comparison 
tests, 
**
P < 0.01 and 
***
P < 0.001, as compared to the control group, respectively. 
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4.3.5 Effects of SN in the presence or absence of MP on GR subcellular 
compartmentalization in Jurkat cells 
To provide morphologic evidence of cells, I further checked the subcellular distribution 
of GR in Jurkat cells after treatment with SN and/or MP by immunofluorescence.  As shown 
in Fig. 5A, treatment with MP (5 ng/mL) facilitated the nuclear translocation of GR.  Similar 
results were observed after incubation of Jurkat cells with 0.03~3 μM SN (Fig. 4-6A).  
Moreover, SN at 0.3 (P<0.05), 1 (P<0.05), and 3 μM (P<0.01) significantly enhanced the 
translocation of GR in nucleus caused by MP (Fig. 4-6B).  These observations were in 















Fig. 4-6  Subcellular localization of GR in Jurkat cells following treatment with 
methylprednisolone (MP) and/or sinomenine (SN).  Cells were pre-treated with SN for 24 
h and harvested at 2 h after MP treatment.  After washing, the cells were fixed and incubated 
with GR antibody, following with Alexa Fluor 488 goat anti-mouse IgG/IgM.  Images were 
examined by a fluorescence microscope and the representative result of three independent 
experiments was shown (A).  Stained nuclear in blue was show in the group of Hoechst.  
Stained GR in green was show in the group of GR.  Expressed GR in nuclear was show in 
the group of Merge.  Signals were quantified using ImageJ program, giving the intensity in 
arbitrary unit (B).  GR intensity was expressed as means ± S.E.M. of three independent 
experiments and analyzed by using Dunnett's Multiple Comparison Test, 
*
P < 0.05 and 
**
P < 
0.01 as compared to the control group, respectively.   
4.3.6 Effects of SN in the presence or absence of MP on GR expression level and GR 
subcellular localization in PBMCs 
To confirm the modulation effects of SN and MP on the GR translocation, PBMCs 
obtained from three healthy subjects were fractionated, and GR expression levels were 
detected by Western blot.  0.3 and 3 μM of SN tended to stimulate the GR expression in 
nucleus (Fig. 4-7A).  Meanwhile, 3 μM of SN influenced the effect of MP on nuclear GR 
expression slightly.  However, the GR expression level rather decreased by the combination 
of 3 μM SN and MP significantly (P<0.05) (Fig. 4-7B).  The combination of MP and SN 
tended to change the distribution ratio more largely (Fig. 4-7C), which meant that SN may 









Fig. 4-7  Expression and subcellular localization of GR in PBMCs after treatment with 
methylprednisolone (MP) and/or sinomenine (SN).  Western blot analysis and 
densitometric quantification of total GR in nuclear (A) and cytoplasmic (B) extracts of 
PBMCs.  Distribution of GR in nuclear/cytoplasmic fractions (C).  Cells were pre-treated 
with SN for 24 h, and harvested at 2 h after MPtreatment.  Nuclear protein extracts were 
normalized to TATA-binding protein (TBP) and cytoplasmic extracts to β-actin.  Data 
represented the mean ± S.E.M. of more than three experiments.  Statistical analyses were 
performed using Dunnett's Multiple Comparison Test, 
*
P < 0.05 as compared to the control 
group. 
4.4 DISCUSSION 
SN tended to suppress the proliferation of PBMCs, and enhance the immunosuppressive 
efficacy of MP.  SN at ≥ 30 μM significantly inhibited the PBMC proliferation (Fig. 4-2A), 
and meanwhile potentiated the GC pharmacodynamics significantly (Fig. 4-2B).   My 
findings in vitro may partially explain why GC combined with SN has been used for the 
treatment of RA patients in China, especially for those who were suffering from refractory 
RA.  A lot of studies reported that SN has also anti-cancer function in breast and many other 
cancers due to its suppressive effects on cell proliferation and apoptosis promotion effects 
[104-106].  Whereas, SN even at high concentration (300 μM) did not show any cytotoxic 
effects in Jurkat T cells (data not shown).  
Some GC-resistant refractory RA patients were known to be accompanied with higher 
P-glycoprotein expression on peripheral lymphocytes [107].  My present data suggested that 
the additional function of SN to enhance MP immunosuppressive efficacy is not related to 
inhibition of P-glycoprotein function in the activated PBMCs.  Although SN at ≥300 μM 




 T cells and 
lymphocytes (Fig. 4-3), the pharmacokinetic parameters of SN in healthy volunteers 
suggested that SN will not accumulate with such higher concentration in serum after intake of 
SN tablet [108].  Yan et al. reported that the Cmax of SN was 246.6 ± 71.2 ng/mL after 
taking of 80 mg SN tablet in healthy volunteers [108].  Chen et al. reported that SN at 100 or 
200 μg/mL exerted significant suppressive effects on P-glycoprotein of human bladder cancer 
74 
253J/DOX cells [24].  However, I did not obtain similar results using the human PBMC 
culture system, which suggested that P-glycoprotein inhibitory function of SN was cell-type 
specific. 
To elucidate the mechanism of the additional function of SN on MP pharmacodynamics, 
I also examined the effects of SN in the presence or absence of MP on GR expression level 
and GR subcellular localization in Jurkat cells.  SN alone at 0.03~3 μM increased the GR 
expression in nucleus, suggesting the maximum efficacy at these concentrations (Fig. 4-5).  
Li et al. reported that 1 μM of SN was enough to stimulate the phosphorylation of the MAPK 
p-38, JNK and ERK on human breast cancer cell lines MDA-MB-231 and MCF-7 [109].  
However, lots of researches disclosed that GR might be phosphorylated by these kinases that 
alter their binding affinity to GC, stability, translocation to the nucleus, binding to DNA, and 
interaction with other proteins, such as transcription factors and molecular chaperones [14, 15, 
110].  The above information may partially explain the phenomenon observed in this 
Chapter that SN at concentrations more than 1 μM showed even lower efficacy on the GR 
translocation.   
However, 1 or 3 μM SN combined with MP exhibited larger efficacy to potentiate the 
GR translocation (Fig. 4-4), which was in accordance with the tendency of the agents on 
PBMC pharmacodynamics (Fig. 4-2B).  The information suggests that some other 
mechanisms were implicated in the additional effect of SN at concentrations of 1~3 μM.  
One of the possible reasons was that higher doses of SN showed mild effect to increase the 
amount of GR in Jurkat cytoplasm (Fig. 4-5B), resulting to bind with MP molecule more 
easily which means that the ability of GR translocation in cytoplasm was enhanced, and thus 
the GR expression in nucleus increased.  On the other hand, SN was reported to prevent 
IL-1β-induced p-NF-κB p65 expression in human fibroblast-like synoviocytes [111].  SN 
also decreased the expression of p-NF-κB p65 in the cardiac tissue of diabetic rats in vivo 
[112].  Activation and/or increase in number of NF-κB might result in attenuation of GC 
efficacy, since proinflammatory transcription factors could interact with GC-GR complex in 
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nucleus [14, 15].  Therefore, the additional effect of SN on GR translocation might be 
related to the regulation of NF-κB signaling pathway by SN. 
SN also regulated the translocation of GR in PBMC culture system.  SN potentiated the 
MP-mediated translocation of GR from cytoplasm to nucleus of PBMCs (Fig. 4-7).  These 
findings in PBMCs were consistent with the results obtained from Jurkat cells.  According to 
my best knowledge, it is the first report that N-Me morphinan alkaloid SN regulated GR 
translocation in human PBMCs and Jurkat T cells.  In my experiment, I also certified that 
GR amounts in the nucleus of PBMCs was less abundant than that in Jurkat T cells, because 
the GR bands in Fig. 4-7A were much weaker than those in Fig. 4-4A and Fig. 4-5A.   
Low- to medium-dose GC has been shown to have not only anti-inflammatory but also 
disease-modifying properties in RA.  However, numerous fears about GC adverse events 
such as osteoporosis, glucose intolerance and cardiovascular disease had arisen in RA patients 
under high-dose GC treatment [113].  In contrast, two meta-analysis reports showed that SN 
alone or in combination with methotrexate is widely used for treating RA in China with better 
clinical efficiency and fewer adverse events [114, 115].  Due to the higher tolerability and 
safety combined with the results of the present research, SN might be a proper agent to 
maintain the low-dose GC immunosuppressive efficacy, and thus decrease the incidence rate 
of GC adverse events.   
4.5 CONCLUSION 
In this Chapter, I provided strong evidence that Japanese Boui-derived alkaloid SN 
potentiates the GC pharmacodynamics.  However, the SN effects had no relation to the 
modification of P-glycoprotein mediated efflux function.  I found that SN itself regulates the 
GR translocation in both Jurkat T cells and human activated PBMCs, and the combination of 
SN and MP showed stronger GR-modulatory activity.  These effects of SN were suggested 
to be beneficial for treatment of RA patients, and thus GC combined with SN would be an 
alternative and reasonable therapeutic approach for RA.   
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GENERAL DISCUSSION AND CONCLUSION 
T cells contribute to a wide spectrum of diseases such as T-cell acute lymphoblastic 
leukemia (T-ALL), autoimmune disorders, and organ transplant rejection [1], and GCs are 
substantially used for treatment of these patients [3].  However, lots of ALL patients show 
poor response to GC monotherapy [4].  High dose of GCs is also preferred for treatment of 
acute allograft rejection, while 30% of the patients receiving kidney transplantation show no 
or an inadequate response to GC which is an important risk factor for inferior renal allograft 
outcome [8].  Faced with these clinical challenges, it is urgent to develop more effective and 
less toxic therapy strategy for controlling diseases, which are implicated with T cell mediated 
diseases.   
TET is a bisbenzylisoquinoline alkaloid derived from a medicinal plant Stephania 
tetrandra S. Moore (中国産防已).  In Chapter 1, I examined the anti-T-ALL effects of TET 
and its analogue CEP, and the underlying mechanism by using a GC resistant human leukemia 
Jurkat T cell line in vitro.  TET and CEP significantly inhibited cell viabilities and induced 
apoptosis in Jurkat cells in dose- and time-dependent manner.  Further investigations showed 
that TET or CEP not only upregulated the expression of apoptosis initiator caspases such as 
caspase-8 and 9, but also increased the expression of effector caspases such as caspase-3 and 
6.  As important markers of apoptosis, p53 and Bax were both upregulated by treatment with 
TET and CEP.  However, TET and CEP paradoxically increased the expression of 
anti-apoptotic proteins such as Bcl-2 and Mcl-1, and activated the survival protein NF-κB, 
leading to high expression of p-NF-κB.  Cell cycle arrest at S phase accompanied by 
increase in the amounts of cyclin A2 and cyclin B1, and decrease in cylcin D1 amount in cells 
treated with TET or CEP will also be implicated as other possible mechanisms.  During the 
process of apoptosis in Jurkat cells, JNK and p38 were activated by treatment with TET or 
CEP.  The PI3K/Akt/mTOR signaling pathway modification appears to play significant role 
in the Jurkat cell apoptosis induced by TET or CEP.  Moreover, TET and CEP seemed to 
downregulate the expressions of p-PI3K and mTOR in an independent way from Akt, since 
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these two drugs strongly stimulated the p-Akt expression.  These results provide 
fundamental insights into clinical application of TET or CEP for the treatment of patients with 
relapsed T-ALL.  Furthermore, the combination of GC and TET or CEP showed synergic 
inhibitory effect on Jurkat cell proliferation, indicating that TET or CEP possibly enhance GC 
pharmacodynamics and overcome GC resistance. 
Because of the synergic effect of TET and MP observed in Chapter 1, I continued to 
investigate the immunosuppressive pharmacodynamics of the combination of TET and MP 
using PBMCs of healthy subjects in Chapter 2.  TET decreased the IC50 value of MP 
significantly, but it showed little toxic effect on the Con A-activated PBMCs.  Both TET and 
MP inhibited the secretion of pro-inflammatory cytokines TNFα and IL-6 and the 
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+
 T cells.  However, TET with or without 





 cells, and lymphocytes.  TET tended to suppress the phosphorylation of MAPK and 
this effect was potentiated by MP.  Meanwhile, TET dose-dependently enhanced the 
inhibitory effect of MP on MOLT-4/DNR T cells expressing high amount of P-glycoprotein 
on the cell membrane, with little effect on the parent MOLT-4 T cells.  This difference might 
result from inhibition of P-glycoprotein efflux function by TET, which consequently increase 
GR translocation into nucleus.  These TET effects were suggested to be beneficial for 
improving the immunosuppressive efficacy of GCs.  Thus, GC combined with TET could be 
a new therapeutic approach to resolve GC-resistance possibly via inhibition of the 
P-glycoprotein function and blocking MAPK signaling pathway, but not affecting on Treg. 
The synergic immunosuppressive effect of TET with MP was also examined in PBMCs 
of hemodialysis patients in Chapter 3, since these patients will be treated by GC after renal 
transplantation.  TET potentiated the MP immunosuppressive pharmacodynamics to inhibit 
T cell mitogen-stimulated proliferation of PBMCs of hemodialysis patients in vitro.  
According to these observations, it seems to be possible to combine MP and TET for 
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treatment of patients to reduce the MP therapeutic dose and thus decline its side effects.  The 
pharmacological efficacy of TET and/or MP correlated with the CRP concentrations of the 
patients, whereas the efficacy did not correlate with other patient-related parameters including 
age, white blood cell counts, and serum creatinine concentrations. 
The botanical sources of Boui are totally different between China and Japan.  Chinese 
Pharmacopeia (2015 edition) lists the Radix Stephaniae Tetrandrae as Boui, while Caulis 
Sinomenii is collected as the herb of Boui in Japanese Pharmacopeia (17
th
 edition).  SN is 
the main active alkaloid of herbal plant Sinomenium acutum (Thunb.) (日本産防已).  In 
Chapter 4, I also evaluated the potential additive effect of SN on GC pharmacodynamics in 
vitro to suppress the proliferation of human T cells.  Although Japanese Boui-derived 
alkaloid SN also potentiated the GC pharmacodynamics like TET did, their action 
mechanisms seemed to be different.  Unlike TET, the effect of SN had no relation to the 
P-glycoprotein mediated efflux function, since SN did not inhibit the P-glycoprotein function 
of PBMCs.  As the underlying mechanism(s) of SN actions, I found that SN regulates the 
GR translocation in both Jurkat T cells and human PBMCs, and the combination of SN and 
MP showed stronger GR-modulatory activity.   
In conclusion, my present study showed that TET and SN, isolated from Chinese Boui 
and Japanese Boui respectively, inhibit the proliferation of activated human T lymphocytes 
and potentiate GC pharmacodynamics by GR translocation modification via different 
signaling pathways.  TET shows cytotoxic effect on GC resistant human leukemia Jurkat T 
cells by inducing apoptosis via multiple signaling pathways.  TET combined with GC is also 
a possible candidate for treatment of patients with relapsed T-ALL.   
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